Η φωτογραφία του Albert Einstein χρησιμοποιείται με την άδεια του HUJ/GreenLight.

ǺȠȘșȒıIJİȞĮȖȓȞȠȣȞIJĮijȐȡȝĮțĮʌȚȠĮıijĮȜȒțĮȚ ǹȞĮijȑȡİIJİ ȅȁǼȈIJȚȢĮȞİʌȚșȪȝȘIJİȢİȞȑȡȖİȚİȢȖȚĮȅȁǹIJĮijȐȡȝĮțĮ ȈȣȝʌȜȘȡȫȞȠȞIJĮȢıIJȘȞ³ȀǿȉȇǿȃǾȀǹȇȉǹ´ Τιμή (Ex-factory): 15.306,72 € Τρόπος διάθεσης: Περιορισμένη ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής.

Για την πλήρη εγκεκριμένη Π.Χ.Π. απευθυνθείτε στην εταιρεία Gilead Sciences Ελλάς M. EΠE, Ριζούντος 2 & Θράκης, 167 77 Ελληνικό. Τηλ.: 210 89 30 100, Fax: 210 96 18 260

W

µ¯É÷º¹½´Í½¿ÅÅÀ¿ÄÁ¿À®Â¡±Á±ÄµÄ±î­½·º»¹½¹º®¯±Ã·

™µÁ±ÀµÍ¿½Ä±ÂÄ·»¿¯îɾ· ±ÀÌ %NQUVTKFKWOFKHHKEKNG ±Àµ»µÅ¸µÁνµÄµÄ¿Å±øµ½µ¯Âñ ±ÀÌÄ¿½º¯½´Å½¿Ä·ÂÅÀ¿ÄÁ¿À®Â

1. Louie TJ et al.

N Engl J Med

2011; 364(5): 422–431.

2. Cornely OA et al.

Lancet Infect Dis

2012; 12: 281–289.

ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ (SPC)

Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακο πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες του τομέα της υγειονομικής περίθαλψης να αναφέρουν οποιεσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 για τον τρόπο αναφοράς ανεπιθύμητων

1.ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ

DIFICLIR 200 mg επικαλυμμένα με λεπτό υμένιο δισκία

2.ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ

Κάθε δισκίο περιέχει 200 mg fidaxomicin. Για τον πλήρη

3.ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ

Επικαλυμμένο με λεπτό υμένιο δισκίο. Δισκία σχήματος κα ψακίου, χρώματος λευκού έως υπόλευκου, με τυπωμένο το

4.ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ

4.1 Θεραπευτικές ενδείξεις: Το DIFICLIR ενδείκνυται σε ενήλικες για τη θεραπεία των λοιμώξεων του Clostridium difficile (CDI), επίσης γνωστή ως διάρροια συσχετιζόμενη με το C. difficile (CDAD) (βλέπε παράγραφο 5.1). Θα πρέπει να λαμβάνονται υπόψη οι επίσημες οδηγίες για την κατάλληλη χρήση των αντιβακτηριακών παραγόντων.

Δοσολογία Ενήλικες και ηλικιωμένοι (≥ 65 ετών): Η συνιστώμενη δόση είναι 200 mg (ένα δισκίο) δύο φορές ημερησίως (μία φορά κάθε 12 ώρες) για 10 ημέρες.

Παιδιατρικός πληθυσμός: δεδομένα. Η ασφάλεια και η αποτελεσμα ετών δεν έχει ακόμη εδραιωθεί. Δεν υπάρχουν διαθέσιμα Νεφρική δυσλειτουργία: 4.4 και 5.2). Δεν θεωρείται απαραίτητη η νικών δεδομένων σε αυτόν τον πληθυσμό, το DIFICLIR πρέπει να χρησιμοποιείται με προσοχή σε ασθενείς με σοβαρή νεφρική δυσλειτουργία (βλέπε παραγράφους Ηπατική δυσλειτουργία: Δεν θεωρείται απαραίτητη η προ σαρμογή της δόσης. Λόγω των περιορισμένων κλινικών δε δομένων σε αυτόν τον πληθυσμό, το DIFICLIR πρέπει να χρη σιμοποιείται με προσοχή σε ασθενείς με μέτρια έως σοβαρή ηπατική δυσλειτουργία (βλέπε παραγράφους 4.4 και 5.2).

Τρόπος χορήγησης Το DIFICLIR προορίζεται για χορήγηση από το στόμα. Το DIFICLIR μπορεί να ληφθεί με ή χωρίς τρο φή. 4.3 Αντενδείξεις: Υπερευαισθησία στη δραστική ουσία ή σε κάποιο από τα έκδοχα που αναφέρονται στην παρά γραφο 6.1. 4.4 Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση Έχουν αναφερθεί αντιδράσεις υπερευαισθη σίας συμπεριλαμβανομένου του σοβαρού αγγειοοιδήματος. Εάν παρατηρηθεί μια σοβαρή αλλεργική αντίδραση κατά τη διάρκεια της θεραπείας με το Dificlir, το φαρμακευτικό προϊ όν πρέπει να διακόπτεται και να λαμβάνονται τα κατάλληλα μέτρα. Μερικοί ασθενείς με αντιδράσεις υπερευαισθησίας ανέφεραν ιστορικό αλλεργίας σε μακρολίδες. Η fidaxomicin πρέπει να χρησιμοποιείται με προσοχή σε ασθενείς με γνω στή αλλεργία στις μακρολίδες. Λόγω των περιορισμένων κλι νικών δεδομένων, η fidaxomicin πρέπει να χρησιμοποιείται με προσοχή σε ασθενείς με σοβαρή νεφρική δυσλειτουργία ή μέτρια έως σοβαρή ηπατική δυσλειτουργία (βλέπε παρά γραφο 5.2) Λόγω των περιορισμένων κλινικών δεδομένων, η fidaxomicin πρέπει να χρησιμοποιείται με προσοχή σε ασθε νείς με ψευδομεμβρανώδη κολίτιδα, κεραυνοβόλο ή απειλη τική για τη ζωή CDI. Δεν υπάρχουν στοιχεία σε ασθενείς με συνοδό φλεγμονώδη νόσο του εντέρου. Η fidaxomicin πρέ πει να χρησιμοποιείται με προσοχή σε αυτούς τους ασθενείς λόγω του κινδύνου της αυξημένης απορρόφησης και τον πι θανό κίνδυνο συστηματικών ανεπιθύμητων αντιδράσεων. Η συγχορήγηση ισχυρών αναστολέων της P-γλυκοπρωτεΐνης, όπως κυκλοσπορίνη, κετοκοναζόλη, ερυθρομυκίνη, κλαρι θρομυκίνη, βεραπαμίλη, δρονεδαρόνη και αμιωδαρόνη δεν συνιστάται (βλέπε παραγράφους 4.5 και 5.2).

Περιγραφή του πληθυσμού ασθενών σε κλινικές δοκιμές Στις δύο κλινικές δοκιμές ασθενών με CDI, το 47,9% (479/999) των ασθενών (σύμφωνα με τον πληθυσμό του πρωτοκόλλου) ήταν ηλικίας ≥ 65 ετών και το 27,5% (275/999) των ασθενών υποβλήθηκε σε ταυτόχρονη θε ραπεία με αντιβιοτικά κατά τη διάρκεια της περιόδου της μελέτης. Το είκοσι τέσσερα τοις εκατό των ασθενών εκ πλήρωσε τουλάχιστον ένα από τα ακόλουθα τρία κριτήρια στη τιμή αναφοράς σε ό,τι αφορούσε τη σοβαρότητα της διαβάθμισης: θερμοκρασία σώματος > 38,5°C, αριθμός dl. Οι ασθενείς με κεραυνοβόλο κολίτιδα και οι ασθενείς με πολλαπλά επεισόδια (οριζόμενα ως περισσότερα του ενός προηγούμενα επεισόδια εντός των προηγούμενων πιθύμητες ενέργειες Περίληψη του προφίλ ασφαλείας Το προφίλ ασφαλείας του DIFICLIR βασίζεται σε δεδομένα από 564 ασθενείς με CDI στους οποίους χορηγήθηκε θεραπεία με fidaxomicin σε μελέτες Φάσης 3. Οι πιο συχνές σχετιζό μενες με τη θεραπεία ανεπιθύμητες ενέργειες ήταν έμετος αναφέρονται οι ανεπιθύμητες ενέργειες που σχετίζονται με τη δις ημερησίως χορήγηση της fidaxomicin στη θεραπεία της λοίμωξης από C. difficile , που αναφέρθηκαν σε τουλάχιστον δύο ασθενείς, παρουσιάζονται ανά κατηγορία οργανικού συ στήματος. Η συχνότητα των ανεπιθύμητων ενεργειών ορίζε ται ως εξής: πολύ συχνές (≥1/10), συχνές (≥1/100 έως <1/10), όχι συχνές (≥1/1.000 έως <1/100), σπάνιες (≥1/10.000 έως <1/1.000), πολύ σπάνιες (<1/10.000), μη γνωστές (δεν μπο ρούν να εκτιμηθούν με βάση τα διαθέσιμα δεδομένα). Εντός κάθε κατηγορίας συχνότητας εμφάνισης, οι ανεπιθύμητες ενέργειες παρατίθενται κατά φθίνουσα σειρά σοβαρότητας.

Κατηγορία/Οργανικό Σύστημα κατά MedDRA

Διαταραχές του ανοσοποιητικού συστήματος - Όχι συχνές: εξάνθημα, κνησμός.- Συχνότητα μη γνωστή: αντιδράσεις υπερευαισθησίας (αγγειοοίδημα, δύσπνοια). Διαταραχές του μεταβολισμού και θρέψης - Όχι συχνές: μειωμένη όρεξη. Διαταραχές του νευρικού συστήματος - Όχι συχνές: ζάλη, κεφαλαλγία, δυσγευσία. Διαταραχές του γαστρεντερικού - Συχνές: έμετος, ναυτία, δυσκοιλιότητα. - Όχι συχνές: κοιλιακή διάταση, μετεωρισμός, ξηροστομία. Διαταραχές του ήπατος - Όχι συχνές: αυξημένη αμινοτρανσφεράση της αλανίνης. Αναφορά πιθανολογούμενων ανεπιθύμητων ενεργειών Η αναφορά πιθανολογούμενων ανεπιθύμητων ενεργειών μετά από τη χορήγηση άδειας κυκλοφορίας του φαρμα κευτικού προϊόντος είναι σημαντική. Επιτρέπει τη συνεχή παρακολούθηση της σχέσης οφέλους-κινδύνου του φαρ μακευτικού προϊόντος. Ζητείται από τους επαγγελματίες του τομέα της υγειονομικής περίθαλψης να αναφέρουν οποιεσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες μέσω: Ελλάδα, Εθνικός Οργανισμός Φαρμάκων, Μεσογείων 284, GR-15562 Χολαργός, Αθήνα, Τηλ: + 30 21 32040380/337, Φαξ: + 30 21 06549585, Ιστότοπος: http://www.eof.gr Κύπρος, Φαρμακευτικές Υπηρεσίες, Υπουργείο Υγείας, CY-1475 Λευκωσία, Φαξ: + 357 22608649, Ιστότοπος: www.

moh.gov.cy/phs

ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:

Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE Leiden, Ολλανδία

ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:

EU/1/11/733/001-004

ΗΜΕΡΟΜΗΝΙΑ ΠΡΩΤΗΣ ΕΓΚΡΙΣΗΣ/ΑΝΑΝΕΩΣΗΣ ΤΗΣ ΑΔΕΙΑΣ:

05/12/2011

ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:

26 Ιουνίου 2014 Λεπτομερή πληροφοριακά στοιχεία για το παρόν φαρμα κευτικό προϊόν είναι διαθέσιμα στον δικτυακό τόπο του Ευρωπαϊκού Οργανισμού Φαρμάκων: http://www.ema.

europa.eu

Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή.

Νοσοκομειακή τιμή : 1325,85 € Περαιτέρω πληροφορίες διατίθενται από τον κάτοχο της άδειας κυκλοφορίας κατόπιν αιτήσεως.

A stellas Pharmaceuticals A.E.B.E.

Θουκυδίδου 1, 14565 Αγ. Στέφανος Αττικής Τηλ.: 210 8189 900, Fax: 210 8189 960

TABLE OF CONTENTS

Welcome Message .................................................................................................. 7 Organization ........................................................................................................... 8 General Information ....................................................................................... 10-12

Venue/Dates & Hours/ Official Language/ Webcasting/ Accreditation/ e-Abstract Book .................................................................................... 10 Social Events/ Registration/ Receipts ........................................................................ 11 Name Badge /Certificate of Attendance/ Exhibition/ Mobile Phones/ Liability and Insurance/ Contact ................................................................................. 12

Scientific Information ..................................................................................... 13-17

Guidelines for Invited Faculty & Presenting Authors ..................................... 13-14 Oral Presentations ............................................................................................................. 15 e-Poster Presentations ..................................................................................................... 16 e-Poster Timetable ............................................................................................................ 17

Scientific Programme ..................................................................................... 19-65

Thursday, March 17, 2016 ........................................................................................ 19-24 Friday, March 18, 2016 ............................................................................................... 25-48 Saturday, March 19, 2016 ......................................................................................... 49-65

Index of Invited Faculty .................................................................................. 67-72 Index of Oral & e-Poster Presentations ......................................................... 73-82 Sponsors/Acknowledgements ............................................................................ 83 Floor plan (Halls) ................................................................................................... 84

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 5

WELCOME MESSAGE

Dear colleagues, On behalf of the Organizing Committee, it is a great pleasure to welcome you to the 8

th

Larissa International Congress of Internal Medicine taking place on 17-19 March, 2016 at Larissa Imperial Hotel, in Larissa, Greece.

The Congress is organized with the joint effort of the Institute of Internal Medicine and Hepatology and the Department of Medicine and Research Laboratory of Internal Medicine of the University of Thessaly Medical School, Larissa, Greece. We are also glad that the Congress is organized in cooperation with the Hellenic Association for the Study of the Liver and the Hellenic Stroke Organization, under the auspices of the University of Thessaly Medical School.

The Organizing and Scientific Committees, aiming to keep up with the educational nature of the previous successful Congresses, have prepared a stimulating scientific programme that will bring topics with broad, interdisciplinary interest to open dialogue and highlight the latest scientific achievements in a variety of diseases encountered in everyday clinical practice of Internal Medicine.

The multi topic scientific programme, given the importance of the international character of the Congress, is designed to feature rather interesting plenary state of-the-art lectures, delivered by leading foreign and Greek experts, round tables designed in collaboration with different Scientific Societies covering hot topics and current issues in the field of Internal Medicine, up-to-date symposia along with satellite lectures and symposia.

Furthermore, the Congress will provide young-and not only-colleagues with a great opportunity to present their work, research and clinical experience through a very important number of oral and poster presentations. We trust that the three days experience in the Congress will become a great opportunity for younger to learn from the older, for experts to share their valuable knowledge and for all to gain from rewarding presentations and discussions.

Best regards, The President of the Organizing Committee

George N. Dalekos

Professor of Medicine, President, Institute of Internal Medicine and Hepatology, President, Hellenic Association for the Study of the Liver, Vice President, Internal Medicine Society of Northern Greece, Head, Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 7

ORGANIZATION

8

Organizers: INSTITUTE OF INTERNAL MEDICINE & HEPATOLOGY, LARISSA, GREECE DEPARTMENT OF MEDICINE & RESEARCH LABORATORY OF INTERNAL MEDICINE, UNIVERSITY OF THESSALY MEDICAL SCHOOL, LARISSA, GREECE Director: Professor G.N. Dalekos ORGANIZING COMMITTEE

President: G.N. Dalekos Members: K. Krapis C. Mandros K.P. Makaritsis G. Ntaios

SCIENTIFIC COMMITTEE Members:

A. Aghemo E. Berge Y. de Boer M. Burnier M. Buti C. Cordonnier M. Cornberg G.L. Daikos G.D. Dimitriadis Μ.-Α. Dimopoulos S. Dourakis J.P. Drenth Μ. Elisaf R. Esteban U. Fischer K. Fountas Α. Garyfallos M. Gacci Ν. Gatselis S. Georgiadou H. Giamarellou C. Gogos S. Gravas D.Ι. Hadjidakis Α. Hatzitolios M. Heneghan H. Hofer R. Jalan T.H. Karlsen Ν.L. Katsilambros

In cooperation with:

G.D. Kitas J. Koskinas C. Labropoulou-Karatza Κ.P. Makaritsis Ε. Maltezos G. Mieli-Vergani H.Μ. Moutsopoulos P. Nilsson G. Ntaios G. Papatheodoridis D. Papazoglou G. Petrikkos S.A. Raptis Ε.I. Rigopoulou Κ. Ritis

HELLENIC ASSOCIATION FOR THE STUDY OF THE LIVER HELLENIC STROKE ORGANIZATION

G. Samonis R. Schmieder A.G. Semb P.P. Sfikakis A. Stefos G. Stergiou E. Tjwa A. Tselepis Ε.V. Tsianos B. Van Der Worp R. Veltkamp Κ. Vemmos D. Vergani D. Vlahakos Κ. Zachou

BOARD OF THE HELLENIC ASSOCIATION FOR THE STUDY OF THE LIVER

President: Treasurer: G.N. Dalekos Vice President: G. Papatheodoridis Gen. Secretary: E. Cholongitas A. Alexopoulou Member: C. Triantos

BOARD OF THE HELLENIC STROKE ORGANIZATION

President: K. Vemmos Vice President: K. Spengos Gen. Secretary: G. Ntaios Treasurer: Members: A. Plomaritoglou A. Hatzitolios H. Milionis K. Takis

Under the auspices of the: UNIVERSITY OF THESSALY MEDICAL SCHOOL, LARISSA, GREECE

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

75 mg, 150 mg, 300 mg 150 mg + 12.5

mg, 300 mg + 12.5

mg, 300 mg + 25 mg

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Lucidel επικαλυµµένα µε λεπτό υµένιο δισκία 75mg, 150mg, 300mg.

Lucidel plus επικαλυµµένα µε λεπτό υµένιο δισκία 150mg+12.5mg, 300+12.5mg, 300+25mg.

ΠΟΙΟΤΙΚΗ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ: Κάθε δισκίο Lucidel περιέχει 75mg, 150mg, 300mg ιρβεσαρτάνης, αντίστοιχα.

Κάθε δισκίο Lucidel plus περιέχει 150mg/12.5mg, 300mg/12.5mg, 300mg/25mg ιρβεσαρτάνης/υδροχλωροθειαζίδης αντίστοιχα.

Για συνταγογραφικές πληροφορίες συµβουλευτείτε την ΠΧΠ ή απευθυνθείτε στην εταιρεία ELPEN.

ELPEN A.E. Φαρµακευτική Βιοµηχανία

Λεωφ. Μαραθώνος 95, Πικέρµι Αττικής 190 09, Τηλ.: 210 60 39 326-9

Γραφεία Επιστηµονικής Ενηµέρωσης

i¡ÈÖÈËÐÈxÈÔÚÕÖÕÇÓÕߥÛÃÔȸÏÓ, i©ÛÔÐÒÃÝ¥ÔÚÐÙÚ³ÙÌÜݞÌÙÙÈÓÕÔÄÒϸÏÓ

GENERAL INFORMATION

Venue LARISSA IMPERIAL HOTEL

182 Farsalon Str., GR 413 35 Larissa, Greece Tel: +30 2410 687600, Fax: +30 2410 687687 Email: [email protected], Website: http://www.larissaimperial.com/

Dates & Hours

Thursday, March 17 th 2016 Friday, March 18 th 2016 Saturday, March 19 th 2016 14:00 - 21:00 08:00 - 21:00 07:45 - 21:00

Official Language

The official language of the Congress is English.

Simultaneous translation (interpretation) will not be provided.

Webcasting

Watch the sessions of the 8th International Congress of Internal Medicine of Central Greece on demand, on http://www.livemedia.com/intmed2016.

Due to the importance of all presentations the organizing committee would like to request for the permission of all speakers to publish their presentations and talks on a specific area on the internet.

Sponsored by

Accreditation

The Congress has been accredited with 16 C.M.E. Credits by the Panhellenic Medical Association.

e-Abstract Book

Abstracts of all Oral and e-Poster Presentations of the Congress will be included in the e-Abstract Book of the Congress. All registered participants are entitled to receive the e-Abstract Book in electronic format (included in the Congress material).

10 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

GENERAL INFORMATION

Social Events WELCOME RECEPTION

Date: Thursday, March 17

th

2016 Time: 21:00 (upon completion of the Opening Ceremony) Location: Larissa Imperial Hotel

(“Achilleas” Hall) Sponsored by Platinum Sponsor

Upon Invitation DINNER

Date: Saturday, March 19

th 2016

Time: 21:30 For more information please check your invitation.

Sponsored by Platinum Sponsor

Registration Registration Fees

(Euros/incl. VAT 23%)

CATEGORY

1 Doctors 1 Trainees 2 Nursing staff 2 Students 3 Other

REGISTRATION FEE 1. Registration for doctors and trainees includes:

• Admission to the Congress area and scientific sessions • • • Admission to the exhibition area Congress material Certificate of Attendance

130,00€ 90,00€ Free Free 40,00€ 2. Registration for nursing staff and students includes

• Admission to the congress area and scientific sessions • • Admission to the exhibition area Certificate of Attendance

3. Registration for other includes:

• Admission to the Congress area and scientific sessions • • • Admission to the exhibition area Congress material Certificate of Attendance

Receipts and Invoices

Receipts and Invoices for Registration, Accommodation & other expenses paid to Conferre Ltd for individual services will be provided to participants during the Congress by the Secretariat, upon request.

Invoices to companies will be issued and sent AFTER the Congress and within one month.

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 11

GENERAL INFORMATION

12

Name Badge-Scanning

All participants, upon confirmation of their registration at the Secretariat, will be provided with a name badge that bears a unique barcode.

It must be clearly understood that barcode badges must be scanned before entering AND after exiting the Lecture Halls.

According to the National Organization of Medicines Regulation participation for at least of 60% of the total duration of the scientific programme must be secured and recorded!

Notes: It is obligatory - for all participants to wear their badges always during the Congress.

Name badges are also necessary for admittance to the social events.

Please be returned to the Secretariat for receiving the Certificate of Attendance.

Time slots for breaks and satellite symposiums/lectures will not be recorded.

Certificate of Attendance

All registered participants are entitled to receive a Certificate of Attendance. The Certificate will be issued on Saturday, March 19 Form at the Secretariat desk.

th 2016 at the end of the Scientific Programme and only upon return of the name badge and the completed Evaluation

Sponsors/ Exhibition

A major exhibition will accompany the Congress, where pharmaceutical and/or equipment/device industries will display relevant products, services and therapeutic developments, reach and interact with the medical community, promote their activities, research and technologies.

Mobile Phones

Everyone is requested to switch off his/her mobile phone while in session Halls.

Liability and Insurance

The Organizers as well as the Organizing-Administrative Bureau will assume no liability for injuries or losses of any nature incurred by participants and/or accompanying persons, or for the damage, loss or theft of their personal property during the Congress. Participants are advised to take out their own health, travel and personal insurances.

Contact Organizing-Administrative Bureau/Secretariat: Conferre Ltd

Stavrou Niarchou Avenue, GR 45110 Ioannina, Greece Tel.: (+30) 26510 68610, Fax: (+30) 26510 68611 E-mail: [email protected], Website: www.conferre.gr

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

SCIENTIFIC INFORMATION

Guidelines for Invited Faculty & Presenting Authors For PPT Presentations

(applies to all presenters) Formal Requirements

Advertising: Advertising of products is prohibited. Be sure your slides are free of any commercial bias (e.g. company names or logos).

Patient anonymity: Kindly make sure that no patient names or any other information allowing the identification of a patient appearing in your presentation.

Copyright reserved: It is the author’s responsibility to ensure that any part of the slide show (figures, tables, images, etc.) is free of any third party right.

Language: The material for the presentation (PowerPoint slides, templates etc) should be prepared in English Language. The presentation should be delivered in English Language.

Technical Requirements

Format: preferable format is MS PowerPoint (pptx or ppsx).

Macintosh presentations will be accepted.*

Versions: up to MS PowerPoint 2010.

Saving of files: For onsite upload, the presentation has to be saved on a USB flash (recommended), CD-ROM or DVD-ROM drive.

Video clips: If you are using embedded video clips in your presentation, please remember to also have the video clips in a separate file (not only in the presentation).

Fonts & character: To avoid any possible compatibility problems, it is preferable not to use any special fonts or special characters.

Onsite presentation

You are kindly requested to deliver your presentation(s) to the technical support personnel at least one (1) hour before the beginning of the Session (in order to ensure on time they run smoothly and to be able of making any possible changes). If the presentation is scheduled early in the morning, you are kindly requested to check your presentation with the technical support personnel the day before.

Your PPT presentation will be available in the lecture hall via computer network.

There will be no possibility of connecting your personal laptop in the lecture hall, due to the very restricted timeslots (row of the presentations).

The main Hall will be equipped with the following:

•

LCD projector with remote control (operated by presenter-no mouse will be available)

•

Screen & Lighted pointer

•

Podium mounted microphone

•

Audience aisle microphones

It is very important to respect the flow of the session and the exact time available for each presentation and therefore you are requested to be consistent with the time slots. It is advisable to rehearse your presentation prior to the meeting to ascertain that the time is not exceeded.

*To the attention of Mac users:

Please make sure to have the suitable adapter and to also have a backup PPT for PC. You are kindly requested to meet with the technical support personnel at least two(2) hours before the beginning of the session, in order to assure compatibility (or backup solutions).

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 13

SCIENTIFIC INFORMATION

MCQ Voting System

MCQ voting system will be available during all sessions.

In accordance with the educative nature of the Congress all speakers are kindly requested to prepare 2-3 multiple choice questions (including 4 possible answers) regarding the topic of their presentation. Speakers will make the questions (preferably at the end of their presentation) and the audience will vote using the electronically voting system. Subsequently, the presenter will give the right answer making the appropriate comments.

Conflict of Interest Disclosure

(applies to all Invited Faculty)

According to the Greek National Organization for Medicines policy, no invited presentation should have any commercial association. Therefore, in compliance with their guidelines, all invited faculty (speakers/chairmen/ moderators etc) participating in the Congress are strictly requested to disclose or indicate potential conflicts of interest (with the Congress sponsors) that might cause a bias.

You are requested (if not already done) to:

1. 2. Advise the sponsors file Declare any potential or actual conflict of interest regarding the above sponsors and topics of the presentation(s) at the or Second Slide of your PowerPoint Presentation (if speaker) orally at the beginning of the session (if chairperson etc) The existence of potential conflicts of interest does not necessarily indicate a bias. However, it is your ethical obligation to inform organizers and participants, so that they become aware of any relationship with the sponsors that might cause unintentional bias. A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, funding for research, investments, family relationship etc.

Publication

All abstracts accepted for Oral & e-Poster Presentations will be included in the e-Abstract Book of the Congress which will be distributed to registered participants within the Congress material.

Presentation Certificate (

applies to Presenting Authors

)

All presenting authors, who will participate in the scientific programme of the Congress with oral or/and e-poster presentations, will be entitled to also receive a Certificate for their presentation.

Certificates will be issued only upon confirmation of complete presentation.

14 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

SCIENTIFIC INFORMATION

Oral Presentations

Duration: Each oral presentation should not exceed 8 minutes. It will be followed by 2 minutes discussion.

Oral Presentations Schedule Thursday, March 17, 2016 14:30-16:00

OP01-OP09

CARDIOVASCULAR MEDICINE

Chairpersons

:

Konstantinos Makaritsis

(Larissa, Greece)

Dwaipayan Sen

(Manchester, UK) Hall OLYMPOS

Friday, March 18, 2016

OP10-OP18

08:00 - 09:30 HEPATOLOGY - GASTROENTEROLOGY

Chairpersons

:

Evangelos Cholongitas

(Thessaloniki, Greece)

Stylianos Karatapanis

(Rhodes, Greece)

OP19-OP27

HEPATOLOGY - GASTROENTEROLOGY - METABOLIC SYNDROME

Chairpersons

:

Konstantinos Mimidis

(Alexandroupolis, Greece)

Dimitrios Samonakis

(Heraklion, Greece)

Saturday, March 19, 2016

OP28-OP34

07:45 - 09:00

Hall ACHILLEAS Hall OLYMPOS

IMMUNOLOGY - ONCOLOGY - HAEMATOLOGY

Chairpersons

:

Matthaios Speletas

(Larissa, Greece)

Christos Tolis

(Ioannina, Greece)

OP35-OP41

Hall OLYMPOS Hall ACHILLEAS

GERIATRIC MEDICINE - INFECTIOUS DISEASES

Chairpersons

:

Efthimia Petinaki

(Larissa, Greece)

Christos Savopoulos

(Thessaloniki, Greece)

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 15

SCIENTIFIC INFORMATION

16

e-Poster Presentations

Duration: Each e-Poster presentation should not exceed 5 minutes. It will be followed by 2 minutes discussion.

e-Poster Presentations Schedule Friday, March 18, 2016 14:00 - 15:30 e-PP01 - e-PP13 (Screen A)

Hall ALKISTIS - THETIDA

CARDIOVASCULAR MEDICINE - METABOLIC SYNDROME

Chairpersons:

Dimitrios Papazoglou

(Alexandroupolis, Greece)

Vasileios Tsimihodimos

(Ioannina, Greece)

e-PP14 - e-PP26 (Screen B) HEPATOLOGY - GASTROENTEROLOGY

Chairpersons:

Melanie Deutsch

(Athens, Greece)

Grigorios Giannoulis

(Athens, Greece) Hall ALKISTIS - THETIDA

e-PP27 - e-PP39 (Screen C) HEPATOLOGY - GASTROENTEROLOGY

Chairpersons:

Christos Triantos

(Patras, Greece)

Vasileios Sevastianos

(Athens, Greece)

e-PP40 - e-PP52 (Screen D) GERIATRIC MEDICINE - IMMUNOLOGY - RHEUMATOLOGY

Chairpersons:

Panagiotis Skendros

(Alexandroupolis, Greece)

Irene Rapti

(Athens, Greece) Hall CHRISALIDA Hall NEFELI

Saturday, March 19, 2016 14:15 - 15:45 e-PP53 - e-PP65 (Screen A) HAEMATOLOGY - ONCOLOGY

Chairpersons:

Georgia Kaiafa

(Thessaloniki, Greece)

Eleni Bouronikou

(Larissa, Greece) Hall ALKISTIS - THETIDA

e-PP66 - e-PP78 (Screen B)

Hall ALKISTIS - THETIDA

INFECTIOUS DISEASES

Chairpersons:

Periklis Panagopoulos

(Alexandroupolis, Greece)

Efthymia Giannitsioti

(Athens, Greece)

e-PP79 - e-PP91 (Screen C) ONCOLOGY - INFECTIOUS DISEASES - MISCELLANEOUS

Chairpersons:

Maria Ioannou

(Larissa, Greece)

Dimitra Dimitropoulou

(Patras, Greece) Hall CHRISALIDA

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

SCIENTIFIC INFORMATION

e-Poster Timetable TIME 14.00-14.07

14.07-14.14

14.14-14.21 14.21-14.28 14.28-14.35

14.35-14.42

14.42-14.49 14.49-14.56 14.56-15.03

15.03-15.10 15.10-15.17

15.17-15.24

15.24-15.30

Hall ALKISTIS-THETIDA

(Screen A) CARDIOVASCULAR MEDICINE - METABOLIC SYNDROME e-PP01 e-PP02 e-PP03 e-PP04 e-PP05 e-PP06 e-PP07 e-PP08 e-PP09 e-PP10 e-PP11 e-PP12 e-PP13 FRIDAY, MARCH 18, 2016

Hall ALKISTIS-THETIDA

(Screen B)

Hall CHRISALIDA

(Screen C) HEPATOLOGY - GASTROENTEROLOGY e-PP14 e-PP15 e-PP16 e-PP17 e-PP18 e-PP19 e-PP20 e-PP21 e-PP22 e-PP23 e-PP24 e-PP25 e-PP26 HEPATOLOGY - GASTROENTEROLOGY e-PP27 e-PP28 e-PP29 e-PP30 e-PP31 e-PP32 e-PP33 e-PP34 e-PP35 e-PP36 e-PP37 e-PP38 e-PP39 SATURDAY, MARCH 19, 2016

Hall ALKISTIS-THETIDA

(Screen A)

Hall ALKISTIS-THETIDA

(Screen B) HAEMATOLOGY - ONCOLOGY INFECTIOUS DISEASES TIME 14.15-14.22

14.22-14.29

14.29-14.36 e-PP53 e-PP54 e-PP55 14.36-14.43 e-PP56 - WITHDRAWN 14.43-14.50 e-PP57 14.50-14.57

14.57-15.04 e-PP58 e-PP59 15.04-15.11

15.11-15.18 15.18-15.25 15.25-15.32

15.32-15.39

15.39-15.45

e-PP60 e-PP61 e-PP62 e-PP63 e-PP64 e-PP65 e-PP66 e-PP67 e-PP68 e-PP69 e-PP70 e-PP71 e-PP72 e-PP73 e-PP74 e-PP75 e-PP76 e-PP77 e-PP78

Hall NEFELI

(Screen D) GERIATRIC MEDICINE - IMMUNOLOGY - RHEUMATOLOGY e-PP40 e-PP41 e-PP42 e-PP43 e-PP44 e-PP45 e-PP46 e-PP47 e-PP48 e-PP49 e-PP50 e-PP51 e-PP52

Hall CHRISALIDA

(Screen C) ONCOLOGY - INFECTIOUS DISEASES - MISCELLANEOUS e-PP79 e-PP80 e-PP81 e-PP82 e-PP83 e-PP84 e-PP85 e-PP86 e-PP87 e-PP88 e-PP89 e-PP90 e-PP91

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 17

ss€{ÌÖ{fÖss€{Ì֓פrmjlØCIKNRSAYNKØØLGØ|g‚ØØLG …‚gØzkq‚€€םkqkšØz{mqt}tqÏkšØgzkonosnkρk؀tØkz‚€mץts‚|ם؁ץÎץg؁mšØ7IM-EDICA

www.winmedica.gr

‚ˆ‡‚ؐ‚jÏztjtšØØؑgqלjqtץtšØƒ‚|ΚؐjtמØØÇg{לsjq‚Ø؃nÎsgØÃlzÖØØ Ãlz֐fpfhhjzÏrØØØØ$K@HJØIMFN VIMLEDICAGQ؈…““‚‹‰Š‡Ø†ns؃s‚€ל€kpšØØ؃ÏgstšØ ÃlzØØØVVVVIMLEDICAGQ

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

14:00

Registration

14:30 - 16:00 ORAL PRESENTATIONS OP01-OP09

Hall OLYMPOS

CARDIOVASCULAR MEDICINE

Chairpersons

:

Konstantinos Makaritsis

(Larissa, Greece)

Dwaipayan Sen

(Manchester, UK)

OP01 ASTRAL PROGNOSTIC SCORE HAS A HIGH PROGNOSTIC ACCURACY IN BOTH THROMBOLYZED AND NON-

THROMBOLYZED PATIENTS WITH ACUTE ISCHAEMIC STROKE 1, 2 Vasileios Papavasileiou, 3 George Ntaios, 4 Christian Weimar (and on behalf of the VISTA collaborators), 5 Kennedy R Lees (and on 7 behalf of the VISTA collaborators), 6 Ashraf Eskandari, Konstantinos Vemmos, 7 Efstathios Manios, 8 Daniel Strbian, 8 Turgut Tatlisumak, 9 Ji Hoe Heo, 9,10 Tae-Jin Song, 11 David J Seiffge, 12 Julia Ferrari, 13 Solène Moulin, 14 Bernard Yan, 15 Bruno J. Weder, 6,16 Carlo W. Cereda, 17 Etsuro Mori, 18 Mohammad Kurniawan, 6 Patrik Michel

1 2 7 Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds, United Kingdom; Kingdom;

VALID ONL Y IF PRESENTED

Sciences, Faculty of Medicines and Health, University of Leeds, United 3 Department of Medicine, Larissa University Hospital, School of Medicine, University of Thessaly, Larissa, Greece; 4 Stroke Unit and Department of Neurology, University Hospital of Essen, Essen, Germany; 5 Institute of Cardiovascular & Medical Sciences, University of Glasgow, BHF Cardiovascular Research Centre, Glasgow, UK; 6 Neurology Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; 8 Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland; 9 Department of Neurology, Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS 10 Ewha Womans University, School of Medicine, Seoul, Korea; 11 Basel, Basel/Switzerland; 12 Stroke Center and Neurology, University Hospital Basel, University of Department of Neurology, St. John´s of God Hospital, Vienna, Austria; 13 Stroke Unit, Department of Neurology, University of Lille, Roger Salengro Hospital, Lille, France, Lille, France; 14 Melbourne, Royal Melbourne Hospital, Australia; 15 St.Gallen, Switzerland; 16 Switzerland, Lugano, Switzeland; 17 18 Melbourne Brain Centre, Department of Neurology, University of Stroke Center, Department of Neurology, Kantonsspital St.Gallen, Stroke Center, Neurology department, Neurocenter of Southern Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan; Stroke Unit, Department of Neurology, Cipto Mangunkusumo National Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia;

OP02 ASTRAL, DRAGON & SEDAN SCORES PREDICT STROKE OUTCOME MORE ACCURATELY THAN STROKE-TREATING

PHYSICIANS 1 4

5

Fotios Gioulekas, Daniel Strbian, 5 2

VALID ONL Y IF PRESENTED

1 Sub-Directorate of Informatics, University General Hospital of Larissa, Larissa, Greece; 2 Department of Medicine, Larissa University Hospital, School of Medicine, University of Thessaly, Larissa, Greece; 3 Comprehensive Stroke Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester M6 8HD, UK; 4 Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland; Stroke Center, Neurology Service, Centre Hospitalier Universitaire

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

OP03 WHICH CVS RISK REDUCTION STRATEGY FITS BETTER TO

CAROTID US FINDINGS? 1 Apostolos Dougalis, 1 Stergios Soulaidopoulos, 1 Evangelos Cholongitas, 1 Parthenis Chalevas, 1 Christos Vettas, 1 Petros Doumtsis, 1 Konstantina Vaitsi, 1 Mariana Diavasti, 1 Evdokia Mandala, 1 Garyfallos Alexandros

1 4 th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki;

OP04 RISK STRATIFICATION FOR RECURRENCE AND MORTALITY IN EMBOLIC STROKE OF UNDETERMINED SOURCE

1 George Athanasakis, 1, 14 Vasileios Papavasileiou, 2 Konstantinos Vemmos, 3 Gregory Y.H. Lip, 2 Elena Koroboki, 2 Efstathios Manios, 2 Anastasia Vemmou, 4 Ana Rodríguez-Campello, 4 Elisa Cuadrado-Godia, 4 Eva Giralt-Steinhauer, 5 Valentina Arnao, 5 Valeria Caso, 5 Maurizio Paciaroni, 6 Exuperio Diez-Tejedor, 6 Blanca Fuentes, 6 Josefa Pérez Lucas, 7 Antonio Arauz, 8 Sebastian F. Ameriso, 8 Maximiliano A. Hawkes, 8 Lucía Pertierra, 8 Maia Gómez-Schneider, 9 Fabio Bandini, 10 Beatriz Chavarria Cano,

1 2

6 7 10 Ana Maria Iglesias Mohedano, 10 Andrés García Pastor, 10 Antonio Gil-Núñez, 11 Jukka Putaala, 11, 12 Turgut Tatlisumak, 13 Miguel A. Barboza, 1 Konstantinos Makaritsis, 1 George Ntaios

VALID ONL Y IF PRESENTED

Department of Clinical Therapeutics, Medical School of Athens, Alexandra Hospital, Athens, Greece; 3 University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK;

4 Stroke Unit, Department of Neurology, Hospital del Mar. Neurovascular Research Group, IMIM-Hospital del Mar (Institut Hospital del Mar d’Investigacions Mèdiques), Universitat Autònoma de Barcelona. Barcelona, Spain 5 Stroke Unit, University of Perugia, Perugia, Italy; Department of Neurology and Stroke Center, La Paz University Hospital - Autónoma University of Madrid, IdiPAZ Health Research Manuel Velasco Suárez. Mexico City, Mexico; 8 9 Department of Neurology, Institute for Neurological Research, FLENI, Buenos Aires, Argentina; Department of Neurology, S. Paolo Hospital, Savona, Italy; 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

10 11 12 13 14 Vascular Neurology Section, Stroke Center, Hospital General Universitario Gregorio Marañón, IiSGM Health Research Institute, Universidad Complutense de Madrid, Spain; Department of Neurology, Helsinki university Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden; Neurosciences Department, Hospital Dr. Rafael A. Calderón Guardia, CCSS. University of Costa Rica, Costa Rica; Comprehensive Stroke Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester M6 8HD, UK;

OP05 PROTOCOL AND GUIDELINE COMPLIANCE IN STROKE MORTALITY:

THE EXPERIENCE OF A COMPREHENSIVE STROKE CENTRE 1 Aisha Iftikhar Syeda, 1 Kaniz Rabia Sindhu, 1,2 Adrian Parry-Jones,

2

1 Jane Molloy, 1,2 Pippa J. Tyrrell, 1 Vasileios Papavasileiou

1 Comprehensive Stroke Centre, Salford Royal NHS, Foundation Trust, Department of Neurosciences; Stroke and Vascular Research Centre, Institute of Cardiovascular

Y IF PRESENTED

OP06 PROGNOSTIC SIGNIFICANCE OF STRESS HYPERGLYCEMIA IN

ACUTE ISCHEMIC STROKE 1 Konstantinos Tziomalos, 1 Panagiotis Dimitriou, 1 Stella Bouziana, 1 Marianna Spanou, 1 Stavroula Kostaki, 1 Stella-Maria Angelopoulou, 1 Maria Papadopoulou, 1 Vasilios Giampatzis, 1 Christos Savopoulos, 1 Apostolos Hatzitolios

1 First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki;

OP07 COGNITION AND NUTRITIONAL FACTORS IN PREDICTING POOR

1

VALID ONL

2 Jason Raw

1 Comprehensive Stroke Centre, Neurosciences Department, Salford Royal NHS Foundation Trust, Manchester, United Kingdom; 2 Department of Geriatric medicine, Fairfield General Hospital, Bury, United Kingdom;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

OP08 PLATELET-MEDIATED RELEASE OF NEUTROPHIL EXTRACELLULAR TRAPS LEADS TO THE EXPOSURE OF ACTIVE TISSUE FACTOR AT THE SITE OF PLAQUE RUPTURE DURING

MYOCARDIAL INFARCTION 1 Konstantinos Kambas, 2 Dimitrios Stakos, 1 Theocharis Konstantinidis, 3 Ioannis Mitroulis, 1,5 Eirini Apostolidou, 4 Stella Arelaki, 1,5 Panagiotis Skendros, 2,6 Stavros Konstantinides, 1,5 Konstantinos Ritis

1 Laboratory of Molecular Hematology, Democritus University of Thrace, Alexandroupolis, Greece; 2 Cardiology Department, Democritus University of Thrace, Alexandroupolis, Greece; 3 Department of Clinical Pathobiochemistry and Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine Technische Universitat Dresden, Dresden; 6 4 Department of Pathology, University General Hospital of Alexandroupolis, Alexandroupolis, Greece; 5 First Department of Internal Medicine, University Hospital of Alexandroupolis, Alexandroupolis, Greece; Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany;

Y IF PRESENTED

OP09 LIPID RED BLOOD CELL MEMBRANES FOLLOWS THE PROGRESSION

OF ISCHEMIC HEART DISEASE: AN NMR-BASED STUDY 1 Ioanna Kastani, 1 Christina Kostara, 2 Georgios Christou, 3 Kostas Tsiafoulis, 2 Vasileios Tsimihodimos, 2 John Goudevenos,

2 3

2 Moses Elisaf, 1 Eleni Bairaktari

1 Laboratory of Clinical Chemistry, Medical School, University of Ioannina, Ioannina, Greece; Department of Internal Medicine, Medical School, University of

VALID ONL

16:00 - 16:30 STATE-OF-THE-ART LECTURE

Hellenic Stroke Organization

Chairperson

:

Konstantinos Fountas

(Larissa, Greece)

Intracerebral haemorrhage: what is the cause?

Charlotte Cordonnier

(Lille, France)

16:30 - 17:00 Coffee break 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

17:00 - 17:30 SATELLITE LECTURE

Defining the role of PCSK9 inhibitor alirocumab in the treatment of hyperlipidemia

Sponsored by Sanofi

17:30 - 19:00 ROUND TABLE Stroke in 2020

Hellenic Stroke Organization

Chairpersons:

Charlotte Cordonnier

(Lille, France)

Konstantinos Vemmos

(Athens, Greece)

Patent foramen ovale: closure or not?

Roland Veltkamp

(London, UK)

Organization of stroke care in the era of endovascular treatment Urs Fischer source?

prevention?

(Bern, Switzerland)

Direct oral anticoagulants for embolic strokes of undetermined George Ntaios

(Larissa, Greece)

Proprotein convertase subtilisin/kexin type 9 inhibitors for stroke Eivind Berge

(Oslo, Norway)

19:00 - 19:30 STATE-OF-THE-ART LECTURE

Chairperson:

Eivind Berge

(Oslo, Norway)

Conflicts of interest: how to handle them? Bart Van Der Worp

(Utrecht, The Netherlands)

19:30 - 19:45 Break

19:45 - 21:00 OPENING CEREMONY

Welcome Inaugural Lecture

Too much or too little medicine Dimitrios Sideris

(Athens, Greece)

21:00 WELCOME RECEPTION

Hall Achilleas

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

08:00 - 09:30 ORAL PRESENTATIONS

OP10-OP18

Hall OLYMPOS

HEPATOLOGY - GASTROENTEROLOGY

Chairpersons

:

Evangelos Cholongitas

(Thessaloniki, Greece)

Stylianos Karatapanis

(Rhodes, Greece)

OP10 NUCLEOS(T)IDE ANALOGUE PROPHYLAXIS AFTER HEPATITIS B IMMUNOGLOBIN WITHDRAWL IS SAFE AND EFFECTIVE AGAINST HEPATITIS B AND D RECURRENCE

AFTER LIVER TRANSPLANTATION 1 Evangelos Cholongitas, 1 Parthenis Chalevas, 1 Theodora Oikonomou, 1 Zoi Valari, 1 Stergios Soulaidopoulos, 1 1 Ioannis Goulis, 2 Ioannis Fouzas, 2 Vasilios Papanikolaou, Evangelos Akriviadis, 3 Themistoklis Vasiliadis

1 4 th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Greece; 2 Department of Transplant Surgery, Medical School of Aristotle University, Greece; 3 3 rd Department of Internal Medicine, Medical School of Aristotle University Papageorgiou General Hospital of Thessaloniki, Greece;

OP11 URINE ALBUMIN-TO-CREATININE RATIO IS ASSOCIATED WITH THE SEVERITY OF LIVER DISEASE, RENAL FUNCTION AND SURVIVAL IN PATIENTS WITH DECOMPENSATED

CIRRHOSIS 1 Evangelos Cholongitas, 1 Ioannis Goulis, 1 Stergios Soulaidopoulos, 1 Parthenis Chalevas, 1 Evangelia Vetsiou, 1 Ioannis Doulgeris, 1 Aikaterini Kolotsiou, 1 Konstantina Vaitsi, 1 Mariana Diavasti, 1 Evangelos Akriviadis

1 4 th Department of Internal Medicine, Hippokration General Hospital, Medical School Aristotle University of Thessaloniki, Greece;

VALID ONL Y IF PRESENTED

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

OP12 ALLOPURINOL ABROGATES THIOPURINE INDUCED LIVER

INJURY 1,2 Polychronis Pavlidis, 3 Azhar Ansari

1 Department of Gastroenterology, King’s College Hospital, London, UK; 2 Department of Experimental Immunobiology and Immunoregulation, Division of Transplantation Immunology and Mucosal Biology, King’s College London, UK; 3 Department of Gastroenterology, East Surrey Hospital, Redhill, UK;

OP13 GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN

CENTRAL GREECE 1 K. Azariadis, 1 N.K. Gatselis, 1 K. Zachou, 1 V. Lygoura, 1 P. Arvaniti, 1 E.I. Rigopoulou, 1 G. Papadamou, 2 G.K. Koukoulis, 1 G.N. Dalekos

1 Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece; 2 Department of Pathology, Medical School, University of Thessaly, Larissa, Greece;

OP14 HEPATIC STEATOSIS AND/OR STEATOHEPATITIS IN PRIMARY

1

BILIARY CIRRHOSIS: AN INNOCENT BYSTANDER OR A

GUILTY PLAYER? V. Lygoura, 1

Y IF PRESENTED

1 P. Arvaniti, 2 G.K. Koukoulis, 1 G.N. Dalekos

1 Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece; 2 Department of Pathology, Medical School, University of Thessaly, Larissa, Greece;

OP15 AUTOIMMUNE HEPATITIS (AIH): IMPACT OF AGE AT DISEASE ONSET ON DISEASE SEVERITY, OUTCOME AND RESPONSE

TO TREATMENT 1 K. Azariadis, 1 P. Arvaniti, 1 K. Zachou, 1 G.N. Dalekos,

VALID ONL

Medicine, Medical School, University of Thessaly, Larissa, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

OP16 PROMPT INITIATION OF INTRAVENOUS CORTICOSTEROIDS PREVENTS DETERIORATION OF ACUTE/SEVERE AUTOIMMUNE HEPATITIS (AS-AIH) AND THE NEED OF LIVER

TRANSPLANTATION (LT) 1 Pinelopi Arvaniti, 1 Kalliopi Azariadi, 1 Nikolaos Gatselis, 1 George N. Dalekos, 1 Kalliopi Zachou

1 Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

OP17 EARLY CHANGE IN FAECAL CALPROTECTIN PREDICTS PRIMARY NON- RESPONSE TO ANTI-TNFΑ THERAPY IN

CROHN’S DISEASE 1 Polychronis Pavlidis, 1 Shraddha Gulati, 1 Patrick Dubois, 1 Guy Chung- Faye, 2 Roy Sherwood, 1 Ingvar Bjarnason, 1 Bu’Hussain Hayee

1 Department of Gastroenterology, King’s College Hospital, London, UK; 2 Department of Biochemistry, Viapath Laboratory, King’s College Hospital, London, UK;

OP18 NEUTROPHIL EXTRACELLULAR TRAPS ARE SPATIALLY DISTRIBUTED IN COLON CANCER TISSUE AND MAY BE CELL APOPTOSIS

Y IF PRESENTED

3 4

1 Athanasios Arampatzioglou, 2 Stella Arelaki, 1 Konstantinos Kambas, 3 Paraskevi Miltiades, 1 Iliana Angelidou, 1 Alexandros Mitsios, 1,4 Panagiotis Skendros, 5 Ioanna Maroulakou, 2 Alexandra Giatromanolaki, 1,4 Konstantinos Ritis

1 Laboratory of Molecular Hematology, Democritus University of Thrace, Alexandroupolis, Greece; 2 Pathology Department, Democritus University of Thrace, Alexandroupolis, Greece; Hematology Department, Democritus University of Thrace,

VALID ONL

Thrace, Alexandroupolis, Greece; 5 Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ACHILLEAS

08:00 - 09:30 ORAL PRESENTATIONS

OP19-OP27

Hall ACHILLEAS

HEPATOLOGY - GASTROENTEROLOGY - METABOLIC SYNDROME

Chairpersons

:

Konstantinos Mimidis

(Alexandroupolis, Greece)

Dimitrios Samonakis

(Heraklion, Greece)

OP19 HIGH IL6 LEVELS ARE POSITIVELY CORRELATED WITH HIGH FREE CORTISOL LEVELS IN PATIENTS WITH ACUTE VARICEAL

BLEEDING 1 Maria Kalafateli, 2 Dimitrios Samonakis, 3 Panagiota Spadidea, 4 Marina Michalaki, 4 Venetsanea Kyriazopoulou,

4

1 Konstantinos Thomopoulos, 3 Athanasia Mouzaki, 1 Christos Triantos

1 Department of Gastroenterology, University Hospital of Patras, Patras, Greece; 2 Department of Gastroenterology, University Hospital of Heraklion, Heraklion, Greece; 3 Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece; Department of Endocrinology, University Hospital of Patras, Patras, Greece;

Y IF PRESENTED

OP20 SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS. MICROBIAL CAUSES AND

CHARACTERISTICS 1 Evangelos Cholongitas, 2 A.M. Markantonatou, 1 Petros Doumtsis, 1 Stergios Soulaidopoulos, 2 O. Gkeka,

2

1 Areti Karasmani, 1 Ioannis Goulis, 2 A. Diamantopoulou, 2 E. Vagdatli, 1 Evangelos Akriviadis

1 4 th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Greece; Microbiology Laboratory, Hippokration General Hospital of

VALID ONL

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ACHILLEAS

OP21 A NATURAL HISTORY STUDY OF DECOMPENSATED ALCOHOLIC CIRRHOSIS: RECENT IMPROVEMENT IN

SURVIVAL 1 Dimitrios N. Samonakis, 1 Aekaterini Augoustaki, 2 Antonios Bertsias, 1 Eirini Theodoraki, 1 Elina Orfanoudaki, 3 Maria Tzardi, 1 Meri Koulentaki, 1 Erminia Matrella, 1 Elias A. Kouroumalis

1 Department of Gastroenterology & Hepatology, University Hospital of Heraklion Crete, Greece; 2 Department of Social Medicine, University of Crete, Greece; 3 Department of Histopathology, University Hospital of Heraklion, Crete Greece;

OP22 TIPS FOR THE MANAGEMENT OF COMPLICATIONS OF LIVER

CIRRHOSIS: A RETROSPECTIVE AUDIT 1 Dimitrios N. Samonakis, 2 Dimitrios Tsetis, 2 Nikolaos Galanakis, 2 Elias Kehagias, 1 Meri Koulentaki, 1 Erminia Matrella,

2

1 Ioannis A. Mouzas, 1 Elias A. Kouroumalis, 2 Adam Hatzidakis

1 Department of Gastroenterology & Hepatology, University Hospital of Heraklion, Crete, Greece; Interventional Radiology Unit, Department of Medical Imaging,

Y IF PRESENTED

OP23 BILLROTH II VERSUS BILLROTH II AND BRAUN 1 Konstantinos Perivoliotis, 1 Alexandros Diamantis, 1 1 Grigorios Christodoulidis, 1 Georgios Tzovaras, Dimitrios Zacharoulis, 1 Konstantinos Tepetes

1 Department of General Surgery, University Hospital of Larissa, Larissa, Greece;

OP24 EXTRAINTESTINAL MANIFESTATIONS AT THE TIME OF DIAGNOSIS IN PATIENTS WITH INFLAMMATORY BOWEL

DISEASE 1

VALID ONL

1 2 Ioannis Familias, Despoina Diakonikola, 1 Georgios Ntetskas, Konstantinos Roufas, 1 Nikitas Katsilis, 1 Foteini Lamprianou, 1

1

Athanasios Hastas, 1 Stylianos Karatapanis

First Department of Internal Medicine, General Hospital of Rhodes, Greece; 2 Gastroenterology Dept, General Hospital of Rhodes, Greece

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ACHILLEAS

OP25 INTESTINAL METAPLASIA IN PATIENTS WITH MULTIFOCAL

ATROPHIC GASTRITIS 1 Nikolaos Chrysanthos, 1 Evagelia Anagnostopoulou, 2 Achileas Melios, 1 Stamatia Patsavela, 3 Pinelopi Korkolopoulou

1 Gastrointestinal Department St George General Hospital of Chania; 2 Anatomopathological Department St George General Hospital of Chania; 3 Anatomopathological Department Athens Medical School;

OP26 METABOLIC PROFILE OF PATIENTS WITH SEVERE MENTAL

DISORDERS IN AN INTERNAL MEDICINE CLINIC 1 Vasileiadis Panagiotis, 1 Mavridis Giorgos, 1 Chliara Maria, 1

1

1 Keramidas Angelos, 1 Papageorgiou Chrysoula, 1 Petrou Danae,

of Psychiatric Hospital;

Y IF PRESENTED

“G.Papanikolaou” - Psychiatric Hospital Thessaloniki, Organic Unit

OP27 THE MEASUREMENT OF SERUM LEVEL OF IL-18 IN TYPE II DIABETIC PATIENTS SUFFERED FROM NEPHROPATHY IN

ZAHEDAN CITY Hossein Ali Khazaei, Zahra Heydari, Javid Dehghan, Amin Khazaei, Amin Rostami, Ehsan Khazaei, Hadi Pordel Ghasemi, Nasereh Arabzadeh

1

VALID ONL

Hall OLYMPOS

09:30 - 10:30 SYMPOSIUM Prostate disease in 2016

Chairperson:

Stavros Gravas

(Larissa, Greece)

Is there a link between benign prostate hyperplasia, prostate cancer and inflammation?

Dionysios Mitropoulos

(Athens, Greece)

Benign prostatic hyperplasia and metabolic syndrome Mauro Gacci

(Florence, Italy)

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

10:30 - 11:00 Coffee Break 11:00 - 13:00 ROUND TABLE

Advances in therapeutic strategies for HBV and HCV

Hellenic Association for the Study of the Liver

Chairpersons:

Rafael Esteban

(Barcelona, Spain)

George N. Dalekos

(Larissa, Greece)

Is HBsAg loss an achievable target for therapy?

Spilios Manolakopoulos

(Athens, Greece)

Difficult to treat patients with HBV infection George Papatheodoridis

(Athens, Greece)

Current challenges in non-HCV-1 genotype therapy Markus Cornberg

(Hannover, Germany)

Cost effectiveness, barriers and access to HCV treatment in Europe Maria Buti

(Barcelona, Spain)

Future treatment options in failures to any antiviral therapy Rafael Esteban

(Barcelona, Spain)

13:00 - 14:00 SATELLITE SYMPOSIUM Chronic hepatitis C: managing “special” populations

Sponsored by Abbvie Pharmaceuticals SA

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

14:00 - 15:30 E-POSTER PRESENTATIONS (Screen A) e-PP01 - e-PP13

Hall ALKISTIS - THETIDA

CARDIOVASCULAR MEDICINE - METABOLIC SYNDROME

Chairpersons:

Dimitrios Papazoglou

(Alexandroupolis, Greece)

Vasileios Tsimihodimos

(Ioannina, Greece)

e-PP01 INCREASED SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR–A AND HYPOVITAMINAEMIA D ARE ASSOCIATED WITH PRECLINICAL ATHEROSCLEROSIS IN

INFLAMMATORY CAUSES OF CHRONIC KIDNEY DISEASE 1 Anna Mavromanoli, 1 Grigorios Dimas, 2 Sofia Spiroglou, 2 Ioannis Karamouzis, 1 Antigoni Spirou, 1 Nikoleta Pirou, 1 Nikolaos Tsiaras, 1 Christos Savvopoulos, 1 Apostolos Hatzitolios, 1 Dimitrios Grekas

1 1 st Propaedeutic Medical Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; 2 Biochemistry Laboratory, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece;

e-PP02 BASELINE CEREBRAL OXIMETRY VALUES IN CARDIO-

1,2 4

4

VALID ONL Y IF PRESENTED

Nikolaos G. Baikoussis, 3 Chrysoula Verra, Miltiadis Matsagas, 1 Stavros Siminelakis, 3 Georgios Kakouris, 5 Georgios Papadopoulos

1 Cardiac Surgery Department, University Hospital of Ioannina, Ioannina, Greece; 2 Cardiovascular and Thoracic Surgery Department, Evangelismos General Hospital of Athens, Greece; 3 Medical Biopathology - Microbiology, Patras General Hospital, Patras, Greece; Vascular Surgery Department, University of Ioannina, Ioannina, University Hospital of Ioannina, Ioannina, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP03 MONITORING OF THE CARDIAC SURGERY PATIENTS WITH SVO2 AND CEREBRAL OXIMETRY; THEIR SIGNIFICANCE AS

EARLY PROGNOSTIC FACTORS 1,2 Nikolaos G. Baikoussis, 3 Chrysoula Verra, 3 Georgios Kakouris, 1

1

Stavros N. Siminelakis, 4 Georgios S. Papadopoulos

Cardiac Surgery Department, University Hospital of Ioannina, Ioannina, Greece; 2 Cardiovascular and Thoracic Surgery Department, Evangelismos General Hospital of Athens, Greece; 3 Medical Biopathology - Microbiology, Patras General Hospital, Patras, Greece; 4 Clinical Anaesthesiology and Intensive Postoperative Care Unit, University Hospital of Ioannina, Ioannina, Greece;

e-PP04 THE CONTRIBUTION OF A SPECIAL LIPID UNIT OF A GENERAL HOSPITAL TO THE SECONDARY PREVENTION OF

ISCHEMIC STROKE IN DIABETICS

2 3

1 Stamatis Papadatos, 2 Christina Dalampira, 3 Adamantios Bourdakis

1 Internal medicine resident, 2 nd Internal medicine clinic Trikala General Hospital, Trikala, Greece;

Y IF PRESENTED

General Hospital, Trikala, Greece;

e-PP05 SHORT AND LONG-TERM COURSE OF PATIENTS WITH

ISCHEMIC STROKE, WITHOUT THROMBOLYTIC THERAPY 1 Apostolos Dougalis, 1 Chalevas Parthenis, 1 Cholongitas Evangelos, 1 Soulaidopoulos Stergios, 1 Lygdi Loukia, 1 Vettas Christos, 1 Kolotsiou Katerina, 1 Doulgeris Ioannis, 1 Mandala Evdokia, 1 Garyfallos Alexandros

1 4 th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki;

VALID ONL

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP06 ASTRAL PROGNOSTIC SCORE HAS A HIGH PROGNOSTIC

ACCURACY IN DIFFERENT ISCHAEMIC STROKE MECHANISMS 1,2 Vasileios Papavasileiou, 3 George Ntaios, 4 Christian Weimar (and on behalf of the VISTA collaborators), 5 Kennedy R Lees 7 (and on behalf of the VISTA collaborators), 6 Nikolaos Kakaletsis, Konstantinos Vemmos, 7 Efstathios Manios, 8 Daniel Strbian, 8 Turgut Tatlisumak, 9 Ji Hoe Heo, 9,10 Tae-Jin Song, 11 David J Seiffge, 12 Julia Ferrari, 13 Solène Moulin, 14 17

6

Bernard Yan, 15 Bruno J. Weder, 6,16 Carlo W. Cereda, Etsuro Mori, 18 Mohammad Kurniawan, 6 Patrik Michel

1 Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds, United Kingdom; 2 School of Medicine, Leeds Institute of Biomedical and Clinical Sciences, Faculty of Medicines and Health, University of Leeds, United Kingdom; 3 Department of Medicine, Larissa University Hospital, School of Medicine, University of Thessaly, Larissa, Greece; 4 Stroke Unit and Department of Neurology, University Hospital of Essen, Essen, Germany; 5 Institute of Cardiovascular & Medical Sciences, University of Glasgow, BHF Cardiovascular Research Centre, Glasgow, UK;

Y IF PRESENTED

7 Department of Clinical Therapeutics, Medical School of Athens, Alexandra Hospital, Athens, Greece; 8 Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland; 9 Department of Neurology, Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea; 10 Ewha Womans University, School of Medicine, Seoul, Korea; 11 Stroke Center and Neurology, University Hospital Basel, University of Basel, Basel/Switzerland; 12 Department of Neurology, St. John´s of God Hospital, Vienna, Austria;

VALID ONL

14 Melbourne, Royal Melbourne Hospital, Australia; 15 Melbourne Brain Centre, Department of Neurology, University of Stroke Center, Department of Neurology, Kantonsspital St.Gallen, St.Gallen, Switzerland;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA 16 Switzerland, Lugano, Switzeland; 17 18 Stroke Center, Neurology department, Neurocenter of Southern Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan; Stroke Unit, Department of Neurology, Cipto Mangunkusumo National Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia;

e-PP07 NON-THROMBOTIC PULMONARY EMBOLISM AFTER INTRA-

ARTICULAR HYALURONIC ACID INJECTION 1 Eleni Paschou, 2 Nikos Sabanis, 3 Eleni Gavriilaki, 2 Christos Dontsos, 4 Petros Faliagkas, 4 Evaggelia Liougka, 4 Charikleia Tsolakidou, 5 Nikolaos Papanikolaou, 4 Eleni Tsotsiou, 4 Stylianos Dolgyras

1 Department of General Practice & Family Medicine, General Hospital of Pella, Edessa, Greece; 2 Department of Nephrology, General Hospital of Pella, Edessa, Greece; 4 3 Hematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanikolaou Hospital, Thessaloniki; Greece; Edessa, Greece;

Y IF PRESENTED

5 Department of General Surgery, General Hospital of Pella, Edessa, Greece;

e-PP08 GUT MICROBIOTA AND ITS IMPACT ON BLOOD PRESSURE 1 Christina Laspa, 2 Eugenia Laspa, 3 Evangelos Kalogiannis, 4 Anna Papakonstantinou, 5 Maria Mironidou-Tzouveleki

1 Medical Doctor, Postgraduate Student, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2 Medical Doctor, Aristotle University of Thessaloniki, Thessaloniki, Greece;

VALID ONL

4 Medical Doctor, Postgraduate Student, Aristotle University of Thessaloniki, Thessaloniki, Greece; 5 Anaesthesiologist, Professor of Pharmacology, A’Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP13 MAY NORADRENALINE MAXIMAL DOSAGE RATE BE

EXPANDED IN LATE SHOCK? 1 Christos Stefanou, 1 Lakis Palazis, 1 Areti Loizou, 1 Chrystalla Timiliotou

1 Limassol General Hospital, ICU;

(Screen B) e-PP14 - e-PP26

Hall ALKISTIS - THETIDA

HEPATOLOGY - GASTROENTEROLOGY

Chairpersons:

Melanie Deutsch

(Athens, Greece)

Grigorios Giannoulis

(Athens, Greece)

e-PP14 SPUR CELL ANEMIA IS ASSOCIATED WITH SEVERE LIVER DISEASE AND POOR OUTCOME IN STABLE PATIENTS WITH

DECOMPENSATED CIRRHOSIS 1 1 Parthenis Chalevas, 1 Evangelos Cholongitas, 1 1 1

1

Stergios Soulaidopoulos, 1 Maria Ioannidou, Evangelia Vetsiou, 1 Alexandros Stamatopoulos, Theodosis Stamatopoulos, Evangelos Akriviadis

4 th

1 Christos Vetas, 1 Ioannis Goulis,

Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Greece;

1 1

Y IF PRESENTED

THE PRESENCE OF HEPATOCELLULAR CARCINOMA AND ADRENAL INSUFFICIENCY IN PATIENTS WITH

DECOMPENSATED CIRRHOSIS Evangelos Cholongitas, 1 Stergios Soulaidopoulos, 1 1 Ioannis Goulis, 1 Parthenis Chalevas, 1 Evangelia Vetsiou, Kleanthi Manika, 1 Petros Doumtsis, 1 Christos Vetas,

1

Theodora Oikonomou, Evangelos Akriviadis

4 th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Greece;

VALID ONL

1

1 2

ILLNESS ANALYSIS Athina Chounta, 2 Kostas Athanasakis, 1 Fani Pliarchopoulou, Dimitrios Mpoumpas

4 th Department of Internal Medicine, “ATTIKON” Hospital, Medical School, National and Kapodistian University of Athens; National School of Public Health, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP20 SOLITARY NECROTIC NODULE (SNN) OF THE LIVER: A CASE

REPORT 1 Nikolaos Papadopoulos, 2 Christos Liatsos, 2 Nikolaos Kyriakos, 3 Dimitra Rontogianni, 4 Eleni Antypa, 5 Stefanos Lachanis, 1 Lazaros Karnesis

1 1 st department of Internal medicine, 401 General Army Hospital of Athens, Greece; 2 Gastroenterology department, 401 General Army Hospital of Athens, Greece; 3 Department of Pathology, Evangelismos Hospital, Athens, Greece; 4 Department of Radiology, Evangelismos Hospital, Athens, Greece; 5 Department of Radiology, 401 General Army Hospital of Athens, Greece;

e-PP21 DUCTAL PLATE MALFORMATIONS: A REPORT OF TWO

CASES 1 Christos Tsaitas, 1 Emmanouil Sinakos, 1 Vassilios Zioganas, 2 Prodromos Hytiroglou, 1 Evangelos Akriviadis

1 4 th Medical Department, Hippokratio Hospital, Aristotle University of Thessaloniki; 2 Department of Pathology, Aristotle University of Thessaloniki;

1

Y IF PRESENTED

CHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA

Stergios Soulaidopoulos, 1 Parthenis Chalevas, 1 Evangelos Cholongitas, 1 Maria Ioannidou, 1 Evangelia Vetsiou, 1 Alexandros Stamatopoulos, 1 Theodosis Stamatopoulos, 1 Petros Doumtsis, 1 Ioannis Goulis, 1 Evangelos Akriviadis

1 4 th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Greece;

VALID ONL

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP23 SPONTANEOUS EPISODES OF BACTEREMIA IN A CIRRHOTIC PATIENT WITH HEPATITIS C- SUCCESFUL MANAGEMENT

WITH NEWER ANTIVIRAL DRUGS 1 Georgios Ntetskas, 1 Vasilios Papastergiou, 2 Ioannis Familias, 1 Mihail Marias, 1 Nikitas Katsilis, 1 Maria Stampori, 1 Athanasios Hastas, 1 Chrysostomos Paellas, 1 Konstantinos Roufas, 1 Stylianos Karatapanis

1 First Department of Internal Medicine, General Hospital of Rhodes, Greece; 2 Gastroenterology Department, General Hospital of Rhodes, Greece;

FINAL SCIENTIFIC PROGRAMME

(Screen C)

Hall CHRISALIDA

e-PP27 - e-PP39

Hall CHRISALIDA

HEPATOLOGY - GASTROENTEROLOGY

Chairpersons:

Christos Triantos

(Patras, Greece)

Vasileios Sevastianos

(Athens, Greece)

e-PP27 DESPITE THE USE OF NUCLEOS(T)IDE ANALOGUES FOR CHRONIC HEPATITIS B, HCC IS OFTEN DEVELOPED IN

ELDERLY PATIENTS 1 Ioannis Ketikoglou, 1 Elina El Nteik, 1 Sotiria Papadaki, 1 Antonis Kyritsis, 1 Emmanuel Koulias

1 Department of Internal Medicine, Hippocratio General Hospital, Athens Greece;

e-PP28 SIGNIFICANT INCREASE OF AUTOIMMUNE DISEASES OF THE

LIVER DURING THE LAST SIX YEARS

2

1 Ioannis Ketikoglou, 2 Christina Zoumbouli, 1 Elina El Nteik, 1 Sotiria Papadaki

1 Department of Internal Medicine, Hippocratio General Hospital, Athens, Greece; Pathology Department, Hippocratio General Hospital, Athens, Greece;

Y IF PRESENTED

e-PP29 HEPATOCELLULAR CARCINOMA IN CRETE: EPIDEMIOLOGY, CLINICAL CHARACTERISTICS AND THE INFLUENCE OF

VARIOUS TREATMENT MODALITIES ON SURVIVAL

2 3

1 Eirini Theodoraki, 1 Maria Kalafateli, 2 Dimitrios Tsetis, 3 Evaggelia Chryssou, 2 Elias Kehagias, 4 Maria Tzardi, 3 Maria Daskalogiannaki, 1 Nikolaos Papiamonis, 1 Ioannis Mouzas, 1 Elias Kouroumalis, 2 Adam Hatzidakis, 1 Dimitrios N. Samonakis

1 Department of Gastroenterology & Hepatology, University Hospital of Heraklion;

VALID ONL

Hospital of Heraklion; 4 Department of Histopathology, University Hospital of Heraklion;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall CHRISALIDA

e-PP30 HEPATOCELLULAR CARCINOMA IN ADULTS CORRELATION

WITH HEPATITIS/AGE AND SEX 1 T. Karaoulani, 2 S. Solomou, 2 Ε. Stavropoulou, 2 E.Sideri, 2 Ε. Uranou, 2 Μ. Pavlou, 2 Κ. Κaramanli, 1 Α. Papanastasiou, 2 Α. Κapatais

1 Biopathology Section οf G.H.N.P.-Agios Panteleimon-G.H.W.A. Agia Varvara, Athens; 2 Pathology department οf G.H.N.P.-Agios Panteleimon-G.H.W.A. Agia Varvara, Athens;

e-PP31 THE SIGNIFICANCE OF A PROMPT EVALUATION OF PATIENTS WITH CIRRHOSIS WHO DEVELOP ENCEPHALOPATHY OR

HEPATORENAL SYNDROME 1 T. Karaoulani, 2 S. Solomou, 2 Ε. Stavropoulou, 2 E.Sideri, 2 Ε. Uranou, 2 Μ. Pavlou, 2 Κ. Κaramanli, 1 Α. Papanastasiou, 2 Α. Κapatais

1 Biopathology Section οf G.H.N.P.-Agios Panteleimon-G.H.W.A. Agia Varvara, Athens; 2 Pathology department οf G.H.N.P.-Agios Panteleimon-G.H.W.A. Agia Varvara, Athens;

CARCINOMA

Y IF PRESENTED

1 Eugenia Laspa, 2 Christina Laspa, 1 Evangelos Kalogiannis, 1 Anna Papakonstantinou, 3 Maria Mironidou-Tzouveleki

1 Medical Doctor, Aristotle University of Thessaloniki; 2 Medical Doctor, Postgraduate Student, Aristotle University of Thessaloniki; 3 Anaesthesiologist, Professor of Pharmacology, A’Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Greece;

FINAL SCIENTIFIC PROGRAMME

Hall CHRISALIDA

e-PP34 IFN-ALPHA RELATED THYROID DISEASE IN HEPATITIS C

PATIENT: A CASE REPORT 1 Ourania Triantafyllou, 1 Konstantinos Krapis, 1 Dimitra Tsionara, 1 George Gkountouras, 1 Flora Koumoutsou, 1 Spiridon Karamagkiolis, 1 Konstantinos Karamitsos

1 Outpatient Clinic, Department of Internal Medicine, General Hospital of Larissa, Greece;

e-PP35 A CASE OF FOCAL SEGMENTAL GLOMERULONEPHRITIS IN A

PATIENT WITH HBV INFECTION 1 Christos Paliouras, 1 Giorgos Ntetskas, 1 Foteini Lamprianou, 1 Konstantinos Roufas, 1 Nikolaos Karvouniaris, 1 Emmanouil Anastasakis, 2 Stylianos Karatapanis

1 Nephrology Department, General Hospital of Rhodes, Rhodes, Greece; 2 1 st Department of Internal Medicine, General Hospital of Rhodes, Rhodes, Greece;

e-PP36 ACUTE PORTAL VEIN THROMBOSIS IN A PATIENT WITH CHRONIC HEPATITIS B TREATED WITH PEGYLATED

INTERFERON- A CASE REPORT 1 Georgios Ntetskas, 1 Vasilios Papastergiou, 1 Mihail Marias, 1 1 1 Nikitas Katsilis, 1 1 1

Y IF PRESENTED

1 First Department of Internal Medicine, General Hospital of Rhodes, Greece;

e-PP37 ACUTE NON-ICTERIC TYPE OF HEPATITIS ACCOMPANIED WITH EOSINOPHILIA AND SKIN RUSH ATTRIBUTED TO FEBUXOSTAT ADMINISTRATION IN A PATIENT WITH

CHRONIC KIDNEY DISEASE 1 2 Eleni Paschou, 2 Eleni Gavriilaki, 2 George Papaioannou, Aliki Tsompanakou, 3 Asterios Kalaitzoglou, 4 Efthimios Pappas, 4 Nikos Sabanis

VALID ONL

2 Hematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanikolaou Hospital, Thessaloniki, Greece; 3 Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece; 4 Department of Nephrology, General Hospital of Pella, Edessa, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall CHRISALIDA

e-PP38 A PSYCHIATRIC PATIENT WITH CHILAIDITI΄S SYNDROME 1 Vasileiadis Panagiotis, 1 Mavridis Giorgos, 1 Keramidas Angelos, 1 Charalampous Charalampos

1 Internal medicine department, General Hospital “G.

Papanikolaou” - Psychiatric Hospital Thessaloniki, Organic Unit of Psychiatric Hospital;

e-PP39 COMPLICATIONS OF UNTREATED ACHALASIA Antonios Alaveras, Lamprini Skorda, Krystalia Diamantidi, Panagiota Chalmouki, Maria Tsekeri, Triantafyllia Toska

Internal Medicine Department, Korgialeneio-Mpenakio Hospital, Athens, Greece; Hall NEFELI

(Screen D) e-PP40 - e-PP52

Hall NEFELI

GERIATRIC MEDICINE - IMMUNOLOGY - RHEUMATOLOGY

Chairpersons:

Panagiotis Skendros

(Alexandroupolis, Greece)

Irene Rapti

(Athens, Greece)

1 1 OSTEOARTHRITIS

Y IF PRESENTED

Grigorios Gkasdaris, 1 Eirini Giovannopoulou, 1 1 Konstantinos Chaniotakis, 1 Eleftherios Chatzimichael, Konstantinos Giatroudakis, 1 Nikolaos Gkantsinikoudis,

1

Stylianos Kapetanakis

Department of Anatomy, Medical School, Democritus University of Thrace, Alexandroupolis, Greece;

e-PP41 TRANSFORAMINAL PERCUTANEOUS ENDOSCOPIC DISCECTOMY FOR LUMBAR DISC HERNIATION IN PARKINSON’S DISEASE: A CASE-CONTROL STUDY WITH A

VALID ONL

1 Grigorios Gkasdaris, 1 Konstantinos Giatroudakis, 1 Konstantinos Chaniotakis, 1 Eleftherios Chatzimichael, 1 Stylianos Kapetanakis

1 Spine Department and Deformities, Interbalkan European Medical Center, Thessaloniki, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall NEFELI

e-PP42 POLYPHARMACY AND ASSOCIATED FACTORS IN CONSECUTIVELY ADMITTED ELDERLY PATIENTS AT THE TIME

OF ADMISSION 1 Panagiota Voukelatou, 1 Ioannis Vrettos, 1 Athina Bitsikokou, 1 Elissavet Sfendouraki, 1 Athanasios Didaskalou, 1 Andreas Kalliakmanis

1 2 nd Department of Internal Medicine, General Oncological Hospital of Kifissia “Ag. Anargyroi”, Athens, Greece;

e-PP43 OSELTAMIVIR INDUCED DELIRIUM: NOTABLE

COMPLICATION IN ELDERLY PATIENTS 1 Liang Yoong Chia, 2 Jia Wern Lee, 1 Francis Lo, 1 Teik Joo Quah

1 General Medicine Department, Tan Tock Seng Hospital; 2 Pharmacy Department, Kk Hospital, Singapore;

e-PP44 NUTRITIONIST AND NEUROLOGICAL REHABILITATION 1 Skoufi Georgia, 1 Kotoula Paraskevi, 1 Lialios Georgios, 1 1 Galliopoulos Demos, 1 Stogianni Eleftheria, 1 Valais Sotirios, Triantaris Apostolos, 1 Stogianni Aikaterini, 1 Papakosta Styliani

1 Arogi Rehabilitation Center, Larisa, Greece;

LITERATURE REVIEW

Y IF PRESENTED

1 Christos Stefanou, 2 Nikolaos Neokleous, 1 Fotini Georgiou, 1 Tzortzi Christiana, 1 Lakis Palazis, 1 Areti Loizou, 3 Ekaterini Choutri, 1 Chrystalla Timiliotou

1 Limassol General Hospital, ICU; 2 Limassol General Hospital, Hematology; 3 Nicosia General Hospital, Pathology;

VALID ONL

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall NEFELI

e-PP46 ANTI-IL-1Β TREATMENT IN A CASE OF SEVERE PUSTULAR

PSORIASIS

6

1 Panagiotis Skendros, 1 Charalampos Papagoras, 2 Ioanna Lefaki, 1 Sadi Mechmet, 3 Alexandra Giatromanolaki, 4 Ioannis Kotsianidis, 5 Matthaios Speletas, 6 Ioannis Theodorou, 1 Vasiliki Dalla, 1 Konstantinos Ritis

1 First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece; 2 State Clinic of Dermatology, Hospital for Skin and Venereal Diseases, Thessaloniki, Greece; 3 Department of Pathology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece; 4 Department of Haematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece; 5 Department of Immunology & Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece; UF d’Histocompatibilité et Immunogénétique, Département d’Immunologie, Groupe Hospitalier Pitié Salpêtrière – Charles Foix, Paris, France;

Y IF PRESENTED

e-PP47 KIKUCHI-FUJIMOTO DISEASE (HISTIOCYTIC NECROTIZING LYMPHADENITIS): REPORT OF A CASE CLINICALLY

MIMICKING SYSTEMIC LUPUS ERYTHEMATOSUS 1 Stauroula Papadopoulou, 1 Kyriakos Chatzopoulos, 1 Aspasia Deliligka, 1 Georgios Hahalis, 1 Christina Nikolaidou, 1 Ioannis Venizelos

1 Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;

FINAL SCIENTIFIC PROGRAMME

Hall NEFELI

e-PP49 DETECTION OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN PATIENTS POSITIVE FOR ANTI-CCP

ANTIBODIES 1 Nikolaos Zotos, 2 Maria Gianniki, 1 Eirini Tatsina, 2 Dimitrios Bougias, 1 Apostolina Papadopoulou, 1 Christos Georgiou, 1 Athanasia Fasouloglou, 1 Evaggelia Chrisostomou, 2 Niki Tsifetaki, 1 Anastasia Pournou

1 Microbiology Department,General Hospital of Ioannina,Greece; 2 Rheumatology Department,General Hospital of Ioannina,Greece;

e-PP50 FULMINANT PRESENTATION OF DERMATOMYOSITIS WITH

CATASTROPHIC COMPLICATIONS

3 4

1 Nikos Sabanis, 2 Eleni Paschou, 3 Eleni Gavriilaki, 4 Eleni Tsotsiou, 2 Tzamal Al-Nofal, 4 Charikleia Tsolakidou, 4 Evaggelia Liougka, 4 Michalis Mpiternas, 4 Alexandra Gaitanaki, 4 Stylianos Dolgyras

1 Department of Nephrology, General Hospital of Pella, Edessa, Greece; 2 Department of General Practice & Family Medicine, General Hospital of Pella, Edessa, Greece; Hematology Department and Hematopoietic Cell Transplantation Edessa, Greece;

Y IF PRESENTED

e-PP51 CASE REPORT: GIANT CELL ARTERITIS AS A REVERSIBLE

CAUSE OF COGNITIVE DECLINE 1 Dwaipayan Sen, 1 Vasileios Papavasileiou, 2 Raymond Hyatt

1 Comprehensive Stroke Centre, Neurosciences Department, Salford Royal NHS Foundation Trust, Manchester, United Kingdom; 2 Department of Geriatric Medicine, Royal Blackburn Hospital, Blackburn, United Kingdom;

VALID ONL

1 Georgios Gkountouras, 1 Melpomeni Barka, 1 Dimitra Tsionara, Georgia Samakidou, 1 Ourania Triantafyllou, 1 Nikolaos Aggelis, 1 Theodora Konstantoula, 1 Konstantinos Krapis, 1 Vasileios Lalos, 1 Konstantinos Karamitsos

1 Department of Internal Medicine, General Hospital οf Larissa, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

15:30-16:00 Leisure time 16:00 - 17:30 ROUND TABLE Resistant hypertension

Chairpersons:

Dimitrios Vlahakos

(Athens, Greece)

Konstantinos Tsioufis

(Athens, Greece)

Diagnosis and evaluation Konstantinos Makaritsis

(Larissa, Greece)

Medical management Michel Burnier

(Lausanne, Switzerland)

New invasive treatment modalities Konstantinos Tsioufis Roland Schmieder

(Athens, Greece)

Long term effects of invasive therapy - Hints for the future

(Nuremberg, Germany)

17:30 - 18:15 SATELLITE SYMPOSIUM The role of echinocandins in clinical practice

Sponsored by Astellas

18:15 - 18:45 Coffee Break 18:45 - 20:15 ROUND TABLE Intestinal microbiota and metabolic disorders

Chairpersons:

Apostolos Hatzitolios

(Thessaloniki, Greece)

Alexandros Tselepis

(Ioannina, Greece)

Microbiota patterns and risk of glucometabolic disease Peter Nilsson

(Malmo, Sweden)

Intestinal microbiota lipid metabolism and atherosclerosis Alexandros Tselepis

(Ioannina, Greece)

Insights into the role of the microbiota in the natural history of obesity Dimitrios Papazoglou

(Alexandroupolis, Greece)

20:15 - 21:00 SATELLITE SYMPOSIUM Recent advances targeting cardiovascular risk reduction and treatment of symptomatic peripheral artery disease

Sponsored by Winmedica

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

07:45 - 09:00 ORAL PRESENTATIONS

OP28-OP34

IMMUNOLOGY - ONCOLOGY - HAEMATOLOGY

Chairpersons

:

Matthaios Speletas

(Larissa, Greece)

Christos Tolis

(Ioannina, Greece) Hall OLYMPOS

OP28 UPDATED DATA OF A NATION-WIDE STUDY OF CLINICAL PHENOTYPES AND TACI MUTATIONS IN PATIENTS WITH

COMMON VARIABLE IMMUNODEFICIENCY (CVID) 1 Eirini Sevdali, 1 Androniki Kapoussouzi, 2 Evangelia Farmaki, 2 Anna Taparkou, 3 Ioannis Kakkas, 4 George Paterakis, 1

4

Anastasios E. Germenis, Society of Hematology 1 Matthaios Speletas,

1,2,3,4

On behalf of the Study Group of Primary Immunodeficiencies of the Hellenic

1 Department of Immunology & Histocompatibility, University of Thessaly, Larissa, Greece; 2 First Department of Pediatrics, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3 Department of Immunology & Histocompatibility, Evangelismos General Hospital, Athens, Greece;

Y IF PRESENTED

OP29 DEFECTIVE POLYMORPHONUCLEAR NEUTROPHIL COMPARTMENT IN COMMON VARIABLE

IMMUNODEFICIENCY (CVID) 1 Gerasimina Tsinti, 1 Anastasios E. Germenis, 1 Matthaios Speletas

1 Department of Immunology & Histocompatibility, University of Thessaly, Larissa, Greece;

OP30 SECONDARY HAEMOPHAGOCYTIC SYNDROME (SHS) REVISITED: A 6-YEARS REAL-LIFE WORLD STUDY ON

VALID ONL

1 Polyxeni Lalou, 1 Mary Boulbou, 1 Sara Georgiadou, 1 Nikolaos Gatselis, 1 Konstantinos Makaritsis, 1 George N. Dalekos, 1 Eirini I. Rigopoulou

1 Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

OP31 TNF REGULATES TIGHT JUNCTION’S CLAUDIN-5 / OCCLUDIN COMPLEX MEDIATED ALVEOLAR EPITHELIAL BARRIER PERMEABILITY IN EXPERIMENTAL MURINE LUNG INJURY

MODEL 1 Vassiliki Karavana, 1 Constantinos Glynos, 2 Christina Magkou, 3 Vreka Malamati, 1 Charikleia S. Vrettou, 1 Sotirios Malachias, 1 Eleni Ischaki, 1 Spyros Mentzelopoulos, 3 George Stathopoulos, 1 Spyros Zakynthinos

1 George P. Livanos and Marianthi Simou Laboratories, Evangelismos Hospital, 1st Department of Pulmonary and Critical Care Unit, University of Athens, Athens, Greece; 2 Pathology Department, “Evangelismos” Hospital, Athens, Greece; 3 Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Achaia, Greece;

OP32 EGFR AND KRAS GENE PROFILE IN PATIENTS WITH COLORECTAL CANCER: CORRELATION WITH

CLINICOPATHOLOGICAL PARAMETERS 1 Maria Samara, 1 Kassiani Kapatou, 1 Maria Ioannou, 1 Roidoula Papamichali, 2 Spyros Potamianos, 2 Andreas Kapsoritakis, 3 Christos Papandreou, 4 Athanasios Athanasiadis, 1 Maria Papathanasiou, 1 George Koukoulis

1 Department of Pathology, School of Medicine, University of Thessaly, Larissa, Greece; 2 Department of Gastroenterology, School of Medicine, University of Thessaly, Larissa, Greece; 3 Department of Medical Oncology, School of Medicine, University of Thessaly, Larissa, Greece; 4 Oncology Department, General Hospital of Larissa, Larissa, Greece;

VALID ONL Y IF PRESENTED

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

OP33 LYMPH NODE RATIO AS A PROGNOSTIC FACTOR IN GASTRIC CANCER FOLLOWING D1 GASTRECTOMY. COMPARISON

WITH THE NEW TNM STAGING SYSTEM 1 Konstantinos Bouliaris, 1 Alexandros Diamantis, 1 Grigorios Christodoulidis, 1 Euaggelos Margonis, 1 Perivoliotis Konstantinos, 1 Erietta Polychronopoulou, 1 Konstantinos Tepetes

1 Department of Surgery-University Hospital of Larissa;

OP34 MTHFR C677T POLYMORPHISM AND THROMBOTIC

COMPLICATIONS IN GREEK SICKLE CELL DISEASE PATIENTS 1 Iakovos Armenis, 1 Vasiliki Kalotychou, 1 Zoe Kontogeorgiou, 1,2 Reveka Tzanetea, 3 Konstantinos Pantos, 4 Konstantinos Konstantopoulos, 2 Ioannis Rombos

1 1 st Department of Internal Medicine, Laiko General Hospital, University of Athens Medical School, Athens, Greece; 2 Metropolitan Hospital, Athens, Greece; 3 Experimental Pharmacology Laboratory, University of Athens Medical School, Athens, Greece; 4 Department of Hematology, Laiko General Hospital, University of Athens Medical School, Athens, Greece;

Y IF PRESENTED

07:45 - 09:00 ORAL PRESENTATIONS

OP35-OP41

Hall ACHILLEAS

GERIATRIC MEDICINE - INFECTIOUS DISEASES

Chairpersons

:

Efthimia Petinaki

(Larissa, Greece)

Christos Savopoulos

(Thessaloniki, Greece)

OP35 ADVERSE DRUG REACTIONS AS A CAUSE FOR HOSPITAL

VALID ONL

1 1 Andreas Kalliakmanis 1 1 Ioannis Vrettos, 1 Athina Bitsikokou, Athanasios Didaskalou,

1 2 nd Department of Internal Medicine, General Oncological Hospital of Kifissia “Ag. Anargyroi”, Athens;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ACHILLEAS

OP36 HIV INFECTION AND HYPERTENSION IN ATHEROSCLEROSIS 1 Galaktion Konstantinidis, 1 Grigorios Dimas, 2 Thomas Tegos, 1 Nikolaos Tsiaras, 1 Maria Larissi, 1 Konstantinos Kapanidis, 1 Evi Mavrantoni, 1 Christos Savopoulos, 1 Anastasios Orologas, 1 Apostolos Hatzitolios

1 1 st Propaedeutic Medical Department of Internal Medicine, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki Greece; 2 1 st Department of Neurology, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki Greece;

OP37 THE ISOLATION OF CANDIDA STRAINS IN BRONCHIAL SECRETIONS SELECTED FROM PATIENTS IN THE INTENSIVE CARE UNIT OF A GENERAL HOSPITAL LOCATED IN WESTERN

GREECE 1 Nikolaos Zotos, 2 Athanasios Margaritis, 3 Maria Gianniki, 1 Eirini Tatsina, 1 Christos Mitsis, 1 Apostolina Papadopoulou,

3

3 Dimitrios Bougias, 3 Niki Tsifetaki, 1 Evaggelia Chrisostomou, 1 Anastasia Pournou

1 Microbiology Department, General Hospital of Ioannina, Greece; 2 Intensive Care Unit, General Hospital of Ioannina, Greece;

Y IF PRESENTED

OP38 A STUDY OF CASES OF BACTEREMIA DURING THE LAST FIVE YEARS IN A GENERAL HOSPITAL IN NORTH WESTERN

GREECE 1 Nikolaos Zotos, 1 Apostolina Papadopoulou, 2 Maria Gianniki, 1 Christos Mitsis, 1 Eirini Tatsina, 1 Christos Georgiou, 2 Dimitrios Bougias, 2 Niki Tsifetaki, 1 Evaggelia Chrisostomou, 1 Anastasia Pournou

1 Microbiology Department, General Hospital of Ioannina, Greece; 2 Rheumatology Department, General Hospital of Ioannina, Greece;

VALID ONL

1

ENTEROCOCCI (VRE) CARRIERS IN A TERTIARY GREEK

HOSPITAL Styliani Sarrou, 1 Zoi Florou, 1 Ergina Malli, 1 Efi Petinaki

1 Department of Microbiology, University Hospital of Larissa, Larissa, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ACHILLEAS

OP40 MOLECULAR EPIDEMIOLOGY AND ANTIMICROBIAL SUSCEPTIBILITY OF CLOSTRIDIUM DIFFICILE ISOLATED

FROM A UNIVERSITY TEACHING HOSPITAL IN GREECE 1 Christina Chatedaki, 1 Ioanna Voulgaridi, 1 Styliani Sarrou, 1 Zoi Florou, 2 Aggelos Stefos, 2 Georgios N Dalekos, 1 Efi Petinaki

1 Department of Microbiology University Hospital of Larissa and Medical School, University of Thessalia, Larissa, Greece; 2 Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

OP41 AUTOCHTHONOUS PLASMODIUM VIVAX INFECTION IN

LARISA: ΟNE OF SIX CASES IN OUR COUNTRY DURING 2015 1

1 2 Thessaly, Larissa;

VALID ONL Y IF PRESENTED

Kalliopi Azariadi, 1 Nikolaos Gatselis, 1 Kalliopi Zachou, 2 Efthymia Petinaki, 1 George N. Dalekos, 1 Sara Georgiadou

Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece; Hall OLYMPOS

09:00 - 10:30 ROUND TABLE Advances in autoimmune hepatitis (AIH)

Chairpersons:

Diego Vergani

(London, UK)

George N. Dalekos

(Larissa, Greece)

Advances in genetics of AIH Ynto de Boer

(Amsterdam, The Netherlands)

EASL CPG guidelines on AIH Harald Hofer

(Vienna, Austria)

AIH in special conditions Michael Heneghan

(London, UK)

AIH in the pediatric population Giorgina Mieli-Vergani

(London, UK)

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

10:30 - 11:00 STATE-OF-THE-ART LECTURE

Chaiperson:

George K. Koukoulis

(Larissa, Greece)

The role of laboratory in the diagnosis and follow-up of autoimmune liver diseases Diego Vergani

(London, UK)

11:00 - 11:30 Coffee Break 11:30 - 13:00 ROUND TABLE Rheumatoid arthritis and the cardiovascular system

Chairpersons:

George D. Kitas

(Dudley, UK)

Petros P. Sfikakis

(Athens, Greece)

Cardiovascular disease in rheumatoid arthritis: Causes, consequences and open questions George D. Kitas

(Dudley, UK)

High grade inflammation and the lipid paradox: implications for treatment Anne Grete Semb

(Oslo, Norway)

Non-invasive assessment of accelerated atherosclerosis in chronic inflammatory conditions Athanasios Protogerou

(Athens, Greece)

Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni

(Athens, Greece)

13:00 - 13:30 STATE-OF-THE-ART LECTURE

Chaiperson:

John Koskinas

(Athens, Greece)

Acute-on-chronic liver failure Rajiv Jalan

(London, UK)

13:30 - 14:15 SATELLITE SYMPOSIUM The Role of sofosbuvir/ledipasvir in HCV cure

Sponsored by Gilead Sciences Hellas

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

14:15 - 15:45 E-POSTER PRESENTATIONS (Screen A) e-PP53 - e-PP65

Hall ALKISTIS - THETIDA

HAEMATOLOGY - ONCOLOGY

Chairpersons:

Georgia Kaiafa

(Thessaloniki, Greece)

Eleni Bouronikou

(Larissa, Greece)

e-PP53 PRIMARY THYROID LYMPHOMA 1 Papadatou Aggeliki, 2 Tsagkarousianos Christos, 1 Moschouris Hipocrates, 3 Aggelidi Maria, 4 Kapros Elias

1 Radiology Department, TZANEIO General Hospital of Piraeus; 2 Surgical Department, General Hospital of Zakinthos; 3 Department of Anesthesia, General Hospital of Zakinthos; 4 Radiology Department, General Hospital of Zakinthos;

e-PP54 EFFECT OF THYROID DYSFUNCTIONS ON BLOOD CELL

COUNT AND RED BLOOD CELL INDICE 1 Nikolaos Vaitsis, 1 Stamatina Aggelakou-Vaitsi

1 Private medical office, Farsala, Greece;

1 Maria Tsitsia, 1 Vasiliki Syrmou, 1 Nikolaos Gatselis, 2 Christos Rountas, 3 George K. Koukoulis, 1 George N. Dalekos, 1 Kalliopi Zachou

1 Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece; 2 Department of Radiology, University Hospital of Larissa, Medical School, University of Thessaly, Larissa, Greece; 3 Department of Pathology, Medical School, University of Thessaly, Larissa, Greece;

VALID ONL

1 Yue Shi, 1 Zarah Lucas, 1 Kavita Kalra

1 Hematology/ Oncology, University of Maryland, Midtown Campus, Baltimore, MD;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP57 A CASE OF MULTIFOCAL BONE LYMPHOMA 2,1 Athanasios Koutsoukis, 1 Georgeta Lascu, 1 Constance Guillaud

1 Acute Medical Unit , APHP Henri Mondor, Creteil, France; 2 Cardiology Department, St Thoma’s Hospital, London, UK;

e-PP58 NON-HODGKIN LYMPHOMA OF THE URINARY BLADDER AS AN INCIDENTAL FINDING FROM PATHOLOGICAL ASSESSMENT OF TISSUE IMPACTED IN FOLEY CATHETER: A

RARE CASE REPORT 1 Kyriakos Chatzopoulos, 1 Stauroula Papadopoulou, 1 Aspasia Deliligka, 1 Georgios Hahalis, 1 Christina Nikolaidou, 1 Ioannis Venizelos

1 Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;

e-PP59 ACQUIRED FANCONI’S SYNDROME SECONDARY TO

MONOCLONAL LIGHT CHAIN GAMMMOPATHY

1

1 Nikos Sabanis, 2 Eleni Paschou, 3 Eleni Gavriilaki, 1 Christos Dontsos, 1 Efthimios Pappas, 1 Sotirios Vasileiou, 3 Georgios Papaioannou

Greece;

Y IF PRESENTED

2 Department of General Practice & Family Medicine, General Hospital of Pella, Edessa, Greece; 3 Hematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanikolaou Hospital, Thessaloniki, Greece;

e-PP60 PORTAL VEIN THROMBOSIS: AN UNEXPECTED FINDING IN A 34-YEAR-OLD MALE WITH ABDOMINAL PAIN: A CASE

REPORT 1 Dimitra Tsionara, 1 Georgia Samakidou,

VALID ONL

1 1 Oyrania Triantafyllou, Konstantinos Karakousis, 1 Theodora Konstantoula, 1 Konstantinos Krapis, 1 Konstantinos Karamitsos

1 Department of Internal Medicine, General Hospital of Larissa;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP61 EVALUATION OF GABAPENTIN IN PATIENTS WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

P. Heras, I. Georgopoulos, M Koutroumbi, A. Stefanopoulos

Department of Internal Medicine of General Hospital of Nafplio;

e-PP62 DYSPNEA AND FATIGUE IN LUNG CANCER PATIENTS 1 Kerasina Papastergiou, 2 Maria Lavdaniti, 3 Sofia Zyga

1 Nurse Thessaloniki, Greece; 2 Nursing Department, Alexander Technological Educational Institute, Thessaloniki, Greece; 3 Nursing Department, University of Peloponnesus, Sparta, Greece;

e-PP63 EFFICACY AND SAFETY OF THE ZOLENDRONIC ACID IN THE MANAGEMENT OF BONE METASTASES FOLLOWING RAPID

INFUSION IN PATIENTS WITH LUNG CANCER P. Heras, I. Georgopoulos, A. Hatzopoulos, M. Koutroumpi, A. Stefanopoulos, M. Hera

Department of Internal Medicine of General Hospital of Nafplio;

e-PP64 SPLENIC INFLAMMATORY PSEUDOTUMOR LIKE FOLLICULAR

DENDRITIC CELL TUMOR: A CASE REPORT 1 3 Thomas Georgiadis, 4

Y IF PRESENTED

1 1st department of Internal medicine, 401 General Army Hospital of Athens, Greece; 2 Department of Radiology, 401 General Army Hospital of Athens, Greece; 3 Department Of Pathology, Hygeia Hospital, Athens, Greece; 4 Department of Surgery, Hygeia Hospital, Athens, Greece;

e-PP65 THE NEEDS AMONG GREEK COLORECTAL CANCER PATIENTS

DURING AND AFTER TREATMENT 1,2 Panagiotis Heras, 1,2 Anastasios Stefanopoulos,

VALID ONL

2 Andreas Hatzopoulos,

1 Hellenic Medical Society of Psychosomatic Problems, Athens, Greece; 2 Department of Internal Medicine General Hospital of Nafplio;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

(Screen B) e-PP66 - e-PP78

Hall ALKISTIS - THETIDA

INFECTIOUS DISEASES

Chairpersons:

Periklis Panagopoulos

(Alexandroupolis, Greece)

Efthymia Giannitsioti

(Athens, Greece)

e-PP66 A PATIENT WITH AUSTRIAN SYNDROME 1 E. Manoulakas, 1 G. Papadamou, 1 G. Ntaios, 1 K. Makaritsis, 1 G.N. Dalekos, 1 S. Georgiadou

1 Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

e-PP67 HUMAN SUBCUTANEOUS DIROFILARIASIS 1 Christos Tsagkarousianos, 2 Aggeliki Papadatou, 3 Maria Aggelidi, 4 Elias Kapros, 5 Irene Katsarou

1 Surgical Department, General Hospital of Zakinthos; 2 Radiology Department, Tzaneio General Hospital of Piraeus; 3 Department of Anesthesia, General Hospital of Zakinthos; 4 Radiology Department, General Hospital of Zakinthos; 5 Department of Nephrology, General Hospital of Zakinthos;

e-PP68 ASEPTIC MENINGITIS AS THE FIRST SIGN IN A PATIENT

BEING INFECTED BY HIV VIRUS 1 Christos Zissis, 1 Efterpi Theodoroula, 1 Dimitra Maritsa, 1

Y IF PRESENTED

1 Athanasios Tsiampalis, 1 Charalampos Karageorgos, Ioannis Lolos, 1 Konstantinos Kalantzis, 1 Stefanos Milonas

1 2 nd Internal Medicine Clinic, General Hospital of Trikala, Trikala, Greece;

e-PP69 PERIPELVIC PYOMYOSITIS IN A DIABETIC PATIENT 1 Spiridoula Mpika, 1 Georgios Gkogkos, 2 Nikitas Karavidas, 1 Ourania Droggoula, 3 Fani Nakopoulou, 1 Aggelos Zormpas

1 First Department of Internal Medicine, General Hospital of Trikala,

VALID ONL

3 Department of Radiology, General Hospital of Trikala, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP70 CASES OF LEPTOSPIROSIS IN A HOSPITAL LOCATED IN NORTH-WESTERN GREECE DURING THE LAST 15 YEARS: A

SERO-EPIDEMIOLOGICAL RETROSPECTIVE STUDY 1 Nikolaos Zotos, 2 Maria Gianniki, 1 Eirini Tatsina, 1 Christos Briasoulis, 1 Christos Mitsis, 1 Lambros Papageorgiou, 1 Sotiria Kitsou, 2 Dimitrios Bougias, 2 Niki Tsifetaki, 1 Anastasia Pournou

1 Microbiology Department, General Hospital of Ioannina, Greece; 2 Rheumatology Department, General Hospital of Ioannina, Greece;

e-PP71 CASES OF LEISHMANIASIS IN NORTH-WESTERN GREECE

DURING A PERIOD OF TWENTY YEARS 1 Nikolaos Zotos, 2 Maria Gianniki, 1 Eirini Tatsina, 2 Dimitrios Bougias, 1 Apostolina Papadopoulou, 1 Christos Georgiou, 1 Lampros Papageorgiou, 1 Evaggelia Chrisostomou, 2 Niki Tsifetaki, 1 Anastasia Pournou

1 Microbiology Department, General Hospital of Ioannina, Greece; 2 Rheumatology Department, General Hospital of Ioannina, Greece;

1 YEARS

Y IF PRESENTED

Nikolaos Zotos, 2 Maria Gianniki, 1 Eirini Tatsina, 2 Dimitrios Bougias, 1 Athanasia Fasouloglou, 1 Eleni Mosheta, 1 George Katagis, 1 Konstantinos Tolis, 1 Niki Tsifetaki, 1 Anastasia Pournou

1 Microbiology Department, General Hospital of Ioannina, Greece; 2 Rheumatology Department, General Hospital of Ioannina, Greece;

e-PP73 ESBL POSITIVE ENTEROBACTERIACEAE STRAINS ISOLATED

VALID ONL

1 Apostolina Papadopoulou, 1 Eirini Tatsina, 2 Maria Gianniki, 2 Dimitrios Bougias, 1 Eleni Mosheta, 1 George Katagis, 1 Athanasia Fasouloglou, 1 Konstantinos Tolis, 1 Anastasia Pournou

1 Microbiology Department,General Hospital of Ioannina,Greece; 2 Rheumatology Department,General Hospital of Ioannina,Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP74 A COMPARATIVE STUDY OF CULTURES OF PERITONEAL FLUID SAMPLES FROM INPATIENTS WITH PERITONITIS

DURING A THREE YEAR PERIOD 1 Nikolaos Zotos, 1 Eirini Tatsina, 2 Maria Gianniki, 2 Dimitrios Bougias, 1 Christos Briasoulis, 1 Christos Mitsis, 1 Lampros Papageorgiou, 1 Sotiria Kitsou, 2 Niki Tsifetaki, 1 Anastasia Pournou

1 Microbiology Department, General Hospital of Ioannina, Greece; 2 Rheumatology Department, General Hospital of Ioannina, Greece;

e-PP75 CULTIVATION RESULTS OF SPECIMENS SELECTED FROM ABSCESSES AND TRAUMAS IN PATIENTS OF A GENERAL

HOSPITAL DURING A PERIOD OF THREE YEARS 1 Nikolaos Zotos, 2 Maria Gianniki, 1 Eirini Tatsina, 1 Lampros Papageorgiou, 1 Apostolina Papadopoulou, 1 Christos Georgiou, 2 Dimitrios Bougias, 1 Evaggelia Chrisostomou, 2 Niki Tsifetaki, 1 Anastasia Pournou

1 Microbiology Department,General Hospital of Ioannina,Greece; 2 Rheumatology Department,General Hospital of Ioannina,Greece;

e-PP76 A CASE OF VISCERAL LEISHMANIASIS- CASE DESCRIPTION 1 1 Nikolaos Zotos, 2

Y IF PRESENTED

3 Dimitrios Bougias, 1 Christos Georgiou, 3 Niki Tsifetaki, 1 Evaggelia Chrisostomou, 1 Anastasia Pournou

1 Microbiology Department, General Hospital of Ioannina, Greece; 2 Pathology Department, General Hospital of Ioannina, Greece; 3 Rheumatology Department, General Hospital of Ioannina, Greece;

FINAL SCIENTIFIC PROGRAMME

Hall ALKISTIS - THETIDA

e-PP78 THE EVALUATION OF ANTIMICROBIAL RESISTANCE IN

HOSPITALIZED PATIENTS AT INTERNAL DISEASES WARD 1 Majlinda Zahaj, 2 Rozeta Luci, 1 Brunilda Subashi, 1 Sonila Nikaj, 1 Evis Alushi

1 Public Health Faculty, University “Ismail Qemali”, Vlore Albania; 2 Regional Hospital of, Vlore, Albania; Hall CHRISALIDA

(Screen C) e-PP79 - e-PP91

Hall CHRISALIDA

ONCOLOGY - INFECTIOUS DISEASES - MISCELLANEOUS

Chairpersons:

Maria Ioannou

(Larissa, Greece)

Dimitra Dimitropoulou

(Patras, Greece)

e-PP79 PRIMARY EWING’S SARCOMA OF THE BREAST 1 Stauroula Papadopoulou, 1 Kyriakos Chatzopoulos, 1 1

1

Aspasia Deliligka, 1 Georgios Hahalis, 1 Christina Nikolaidou, Ioannis Venizelos

Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;

Y IF PRESENTED

e-PP80 SOLITARY FIBROUS TUMOR OF THE SPINAL CORD: A RARE

CASE REPORT 1 Stauroula Papadopoulou, 1 Kyriakos Chatzopoulos, 1 Aspasia Deliligka, 1 Georgios Hahalis, 1 Christina Nikolaidou, 1 Ioannis Venizelos

1 Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;

e-PP81 OSTEOBLASTIC METASTASES AS A PRESENTATION OF

SIGNET RING CELL GASTRIC CARCINOMA

VALID ONL

1 Kyriakos Chatzopoulos, Aspasia Deliligka, 1 Christina Nikolaidou, 1 Ioannis Venizelos

1 Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall CHRISALIDA

e-PP82 LYMPHOEPITHELIAL-LIKE CARCINOMA OF THE PAROTID

GLAND: CASE REPORT 1 Stauroula Papadopoulou, 1 Kyriakos Chatzopoulos, 1 Aspasia Deliligka, 1 Georgios Hahalis, 1 Christina Nikolaidou, 1 Ioannis Venizelos

1 Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;

e-PP83 ASSESSMENT OF DEPRESSION IN PATIENTS WITH

COLOSTOMY USING THE CES-DEPRESION SCALE 1 Maria Lavdaniti, 2 Evagelos Dimopoulos, 3 Kerasina Papastergiou, 4 Helen Dokoutsidou, 5 Sofia Zyga

1 Nursing Department, Alexander Technological Educational Institute, Thessaloniki, Greece; 2 Economic, Athens, Greece; 3 University of Thessaly , Larissa, Greece; 4 Nursing Department, TEI of Athens, Athens, Greece; 5 Nursing Department,University of Peloponesus, Sparta, Greece;

e-PP84 INFLAMMATORY MYOFIBROBLASTIC TUMOR OF THE

PAROTID GLAND 1 Kyriakos Chatzopoulos, 1 Stauroula Papadopoulou, 1 1 Aspasia Deliligka, Ioannis Venizelos 1

Y IF PRESENTED

1 Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;

e-PP85 MALARIA - REAPPEARANCE OF “FORGOTTEN” INFECTIOUS

DISEASES 1 Christos Zissis, 1 Dimitra Maritsa, 1 Athanasios Tsiabalis, 1 Euterpi Theodoroula, 1 Charis Karageorgos, 1 Ioannis Lolos, 1 Dimitris Oikonomou, 2 Eleni Gatsa, 3 Vasiliki Samara, 1 Stefanos Milonas

VALID ONL

2 Greece; 3 Microbiology Lab, General Hospital of Trikala, Trikala, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall CHRISALIDA

e-PP86 CANDIDA PARAPSILOSIS PROSTHETIC VALVE

ENDOCARDITIS 1 Spiridoula Mpika, 2 Nikitas Karavidas, 1 Georgios Gkogkos, 1 Apostolos Tziortziotis, 1 Anastasia Theodora Kalliara, 1 Aggelos Zormpas

1 First Department of Internal Medicine, General Hospital of Trikala, Greece; 2 Department of Cardiology,General Hospital of Trikala, Greece;

e-PP87 RUPTURED PULMONARY HYDATIC CYST 1 Papadatou Aggeliki, 2 Tsagkarousianos Christos, 1 Moschouris Hipocrates, 3 Kapros Elias, 2 Mauraki Eugenia

1 Radiolody Department, TZANEIO General Hospital of Piraeus; 2 Surgery Department, General Hospital of Zakinthos; 3 Radiology Department, General Hospital of Zakinthos;

e-PP88 NITROFURANTOIN IN EVERY-DAY CLINICAL PRACTICE: BE

AWARE OF SIDE-EFFECTS 1 Marianna Bakarozi, 1 Aggelos Stefos, 1 Mary Boulbou, 1 Asterios Polyzos, 1 George N. Dalekos, 1 Eirini I. Rigopoulou

1 Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

e-PP89 GUILLAIN-BARRE SYNDROME DEVELOPMENT FOLLOWING A

BITE BY A CENTIPEDE- A CASE REPORT 2 2 1 1

1

Y IF PRESENTED

Anastasia Kaliotzoglou, 2 Foteini Alourda, 1 Georgios Ntetskas, Ioannis Lapis, 1 Mihail Marias, 1 Eustathia Anastasiou, Maria Stampori, 1 Georgios Psellakis, 1 Nikitas Katsilis, Stylianos Karatapanis

2 First Department of Internal Medicine, General Hospital of Rhodes, Greece; Neurology Dept, General Hospital of Rhodes, Greece;

e-PP90 A MILLLER FISHER SYNDROME IN A YOUNG WOMAN- A

CASE REPORT

VALID ONL

1 1

1

Foteini Alourda, 1 Georgios Ntetskas, 1 Euthymia Anastasiou, 2 Anastasia Kaliotzoglou, 2 Ioannis Lapis, Georgios Zaharis, 1 Mihail Marias, 1 Vasilios Papastergiou, Stylianos Karatapanis

2 First Department of Internal Medicine, General Hospital of Rhodes, Greece; Neurology Dept, General Hospital of Rhodes, Greece;

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall CHRISALIDA

e-PP91 EPILEPTIC FITS IN A PATIENT WITH THE SYNDROME OF HYPERZINCAEMIA AND HYPERCALPROTECTINAEMIA - A

CASE REPORT 2 Foteini Alourdani, 2 Anastasia Kaliotzoglou, 1 1

1

Georgios Ntetskas, Maria Stampori, 1

VALID ONL

2 1

Y IF PRESENTED

1 Vasilios Papastergiou, 1 Stylianos Karatapanis

2 Neurology Dept, General Hospital of Rhodes, Greece; Hall OLYMPOS

15:45 - 16:00 Leisure time 16:00 - 17:30 ROUND TABLE Invasive fungal infections (IFI)

Chairperson:

George Petrikkos

(Athens, Greece)

Allogeneic hematopoietic stem cell transplantation in patients with prior invasive aspergillosis Nikolai Klimko

(Saint Petersburg, Russia)

Invasive fungal infections in solid organ transplants

Emmanuel Roilides

(Thesalloniki, Greece)

Newer guidelines for the treatment of invasive candidiasis in non- neutropenic patients Sarah Georgiadou

(Larissa, Greece)

Newer (ECIL and ESCMID/ECMM) guidelines in the treatment of IFI in leukemic patients Anna Skiada

(Athens, Greece)

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

FINAL SCIENTIFIC PROGRAMME

Hall OLYMPOS

17:30 - 19:00 ROUND TABLE Inflammatory bowel disease (IBD) and the liver

Chairpersons:

Alessio Aghemo

(Milan, Italy)

Joost P.H. Drenth

(Nijmegen, The Netherlands)

Management of viral hepatitis in patients with IBD Alessio Aghemo

(Milan, Italy)

Primary sclerosing cholangitis Tom Hemming Karlsen

(Oslo, Norway)

Liver enzyme elevations as a result from IBD therapy Joost P.H. Drenth Reasons for ALT elevation in IBD: autoimmune liver disease?

Eric Tjwa

(Nijmegen, The Netherlands) (Nijmegen, The Netherlands)

19:00 - 19:30 Coffee Break 19:30 - 21:00 SATELLITE SYMPOSIUM Chronic hepatitis C treatment management: From clinical trials to clinical practice!

Sponsored by Bristol-Myers Squibb

21:30 Dinner

Upon invitation

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

̮͊͂Ĭ͆͐͊͒͒Ш͓͔͍͓͆͐͆͑͒͂̈́͏͕̈́͐͂͊͋Т͑Ĭ͈͌͐͏͕͏͐Ф͔͆͑͒Ƅ̓͏͔͔͓͌͆͆Ф͓͆ ͓͈͍̺͆͐Ф͈͈͓͈͓͌͗̀͂͐͂͋͐͊͒͊͋Ъ͍͓͏͔̺͐͏ЦШ͍͓͏͑

Υπεύθυνος Άδειας Κυκλοφορίας

MSD A.Φ.Β.Ε.Ε Αγ. Δημητρίου 63, 174 56 Άλιμος, Αθήνα, Τηλ.: 210 9897300

www.msd.gr

Συμπροώθηση από την εταιρεία:

BIANEΞ Α.Ε.

ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

LICENSEE / DISTRIBUTOR OF MERCK SHARP & DOHME, Division of MERCK & Co., Inc., Whitehouse Station, N.J., USA

Γραφεία Επιστημονικής Ενημέρωσης

ΑΘΗΝΑ: Οδός Τατοΐου, 146 71 Ν. Ερυθραία, Τηλ.: 210 8009111 t&NBJMNBJMCPY!WJBOFYHSt INTERNET: http://www.vianex.gr

tȠȝȪȪșȣȧȥȡȢȟΑκαδήμου 113, Κόμβος Μακρυγιάννη, Εύοσμος Θεσσαλονίκης, TK 56224, Τηλ: 2310 833893 tȨșȫȩșΜαιζώνος 131, Τηλ.: 2610 221397

INDEX OF INVITED FACULTY

AGHEMO ALESSIO

Professor of Gastroenterology, 1 Ca' Granda Ospedale Maggiore, University of Milan, Milan, Italy st Division of Gastroenterology, Fondazione IRCCS

BERGE EIVIND

Stroke Physician, Department of Internal Medicine, Oslo University Hospital, Oslo, Norway

BOURONIKOU ELENI

Hematology Consultant, Hematology Department, University General Hospital of Larissa, Larissa, Greece

BURNIER MICHEL

Professor of Medicine, Head, Division of Nephrology and Hypertension Consultation, University Hospital of Lausanne, Lausanne, Switzerland

BUTI MARIA

Professor of Medicine, Department of Internal Medicine II and Hepatology, BarcelonaVall d'Hebron University Hospital, Barcelona, Spain

CHOLONGITAS EVANGELOS

Assistant Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 4 th Academic Department of Internal Medicine, Hippokration General Hospital of Thessaloniki,

Greece Thessaloniki,

CORDONNIER CHARLOTTE

Professor of Neurology, Faculty of Medicine, University of Lille, Head, Neurovascular Intensive Care Unit, Department of Neurology & Stroke Unit, Lille University Hospital, Lille, France

CORNBERG MARKUS

Professor of Gastroenterology, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

DALEKOS GEORGE

Professor of Medicine, President, Institute of Internal Medicine and Hepatology, President, Hellenic Association for the Study of the Liver, Vice President, Internal Medicine Society of Northern Greece, Head, Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece

DE BOER YNTO

Gastroenterologist, Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands

DEUTSCH MELANIE

Assistant Professor of Hepatology-Internal Medicine, Faculty of Medicine, School of Health Sciences, National & Kapodistrian University of Athens, Athens, Greece

DIMITROPOULOU DIMITRA

Physician in Internal Medicine and Infectious Diseases Specialist, Patras, Greece

DRENTH JOOST

Professor of Gastroenterology, Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 67

INDEX OF INVITED FACULTY

ESTEBAN RAFAEL

Professor of Medicine, Head, Department of Internal Medicine II & Hepatology, Vall d'Hebron University Hospital, Barcelona, Spain

FISCHER URS

Professor for Acute Neurology and Stroke, Co-Director Clinical Trial Unit Bern, University of Bern, Bern, Switzerland

FOUNTAS KONSTANTINOS

Associate Professor of Neurosurgery, Faculty of Medicine, University of Thessaly, Director, Department of Neurosurgery, University General Hospital of Larissa, Larissa, Greece

GACCI MAURO

Urology Consultant, Department of Urology, University of Florence, Italy

GEORGIADOU SARAH

Internal Medicine Consultant and Infectious Diseases Specialist, Department of Medicine & Research Laboratory of Internal Medicine, University Hospital of Larissa,

Larissa, Greece

GIANNITSIOTI EFTHΥMIA

Internal Medicine Consultant and Infectious Diseases Specialist, 4 th Department of Internal Medicine, University of Athens Medical School, “Attikon” University Hospital of Athens, Athens, Greece

GIANNOULIS GRIGORIOS

Director, Department of Hepatology, Metropolitan Hospital, Athens, Greece

GRAVAS STAVROS

Associate Professor of Urology, University of Thessaly Medical School, University Hospital of Larissa, Larissa, Greece

HATZITOLIOS APOSTOLOS

Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Vice President, Internal Medicine Society of Northern Greece, Director, 1

HOFER HARALD

st Propaedeutic Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloniki, Greece

HENEGHAN MICHAEL

Clinical Director for Liver Services, Consultant Hepatologist & Reader in Hepatology, Institute of Liver Studies, King's College Hospital, London, United Kingdom Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

IOANNOU MARIA

Associate Professor of Pathology, Faculty of Medicine, School of Health Sciences University of Thessaly, Larissa, Greece

JALAN RAJIV

Professor of Hepatology, Editor in Chief, Journal of Hepatology, Liver Failure Group, Institute for Liver and Digestive Health, University College London Medical School, London, UK

68 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

INDEX OF INVITED FACULTY

KAIAFA GEORGIA

Lecturer of Hematology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 1 st Medical Propedeutic Department of Internal Medicine AHEPA Hospital Thessaloniki, Greece

KARATAPANIS STYLIANOS

Director, 1 st Department of Internal Medicine, General Hospital of Rhodes, Rhodes, Greece

KARLSEN TOM HEMMING

Professor at Research Institute of Internal Medicine, Leader of Norwegian PSC Research Center, Oslo University Hospital, Oslo, Norway

KITAS GEORGE

Professor of Clinical Rheumatology, Arthritis Research UK Centre for Epidemiology, University of Manchester, Professor of Behavioural Rheumatology, College of Health and Life Sciences, University of Birmingham, Head of Research and Development – Academic Affairs, Dudley Group NHS Foundation Trust (Teaching), Clinical Research Unit, Russells Hall Hospital, Dudley, UK

KLIMKO NIKOLAI

Professor, Head of Department of Clinical Mycology, Allergy and Immunology, I. Mechnikov North-Western State Medical University, Saint Petersburg, Russia

KOSKINAS JOHN

Professor of Internal Medicine Hepatology, Faculty of Medicine, School of Health Sciences, National & Kapodistrian University of Athens, 2 nd Department of Internal Medicine, Hippokration General Hospital of Athens, Athens, Greece

KOUKOULIS GEORGE

Professor of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

MAKARITSIS KONSTANTINOS

Associate Professor of Medicine, Department of Medicine & Research Laboratory of Internal Medicine, University of Thessaly Medical School, University Hospital of Larissa, Larissa, Greece

MANOLAKOPOULOS SPILIOS

Associate Professor in Medicine Gastroenterology, Faculty of Medicine, National & Kapodistrian University of Athens, Athens, Greece

MAVROGENI SOPHIE

Cardiologist, Onassis Cardiac Surgery Center, Athens, Greece

MIELI VERGANI GIORGINA

Emeritus Professor of Paediatric Hepatology, Paediatric Liver, GI & Nutrition Centre, King’s College Hospital, London, UK

MIMIDIS KONSTANTINOS

Associate Professor of Internal Medicine Hepatology, First Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 69

INDEX OF INVITED FACULTY

MITROPOULOS DIONYSIOS

Professor of Urology, Faculty of Medicine, School of Health Sciences, National & Kapodistrian University of Athens, Athens, Greece

NILSSON PETER

Professor of Clinical Cardiovascular Research, Department of Clinical Sciences, Lund University, Skane University Hospital, Malmo, Sweden

NTAIOS GEORGE

Assistant Professor of Medicine, Department of Medicine & Research Laboratory of Internal Medicine, University of Thessaly Medical School, University Hospital of Larissa, Larissa, Greece

PANAGOPOULOS PERIKLIS

Assistant Professor of Internal Medicine, 2 nd University Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece

PAPATHEODORIDIS GEORGE

Professor of Medicine & Gastroenterology, Faculty of Medical School, National and Kapodistrian University of Athens, Director, Academic Department of Gastroenterology, Laiko General Hospital of Athens, Greece

PAPAZOGLOU DIMITRIOS

Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Democritus University of Thrace, 2 nd Academic Department of Internal Medicine, University General Hospital of Evros, Alexandroupolis, Greece

PETINAKI EFTHIMIA

Associate Professor of Microbiology, Faculty of Medicine, Department of Microbiology, University of Thessaly, Director of Microbiology Laboratory, University Hospital of Larissa, Larissa, Greece

PETRIKKOS GEORGE

Emeritus Professor of Internal Medicine

and Infectious Diseases National and Kapodistrian University of Athens, Professor of Immunology, Medical Microbiology and Infectious Diseases Medical Training Coordinator European University Cyprus

PROTOGEROU ATHANASIOS

Associate Professor of Internal Medicine, Faculty of Medicine, University of Athens, Athens, Greece

RAPTI IRENE

Consultant Physician in Internal Medicine and Hepatology, Athens Medical Center, Athens, Greece

ROILIDES EMMANUEL

Professor of Paediatrics & Infectious Diseases, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 3 of Paediatrics, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece rd Academic Department

SAMONAKIS DIMITRIOS

Consultant in Gastroenterology and Hepatology, University Hospital of Heraklion Crete, Greece

70 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

INDEX OF INVITED FACULTY

SAVOPOULOS CHRISTOS

Associate Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Stroke Unit, 1st Propaedeutic Department of Internal Medicine, “AHEPA” University Hospital of Thessaloniki, Thessaloniki, Greece

SCHMIEDER ROLAND

Professor of Internal Medicine, Nephrology and Hypertension, Head, Clinical Research Centre, Vice Chair, Department of Nephrology and Hypertension, University Hospital Erlangen, Nuremberg, Germany

SEMB ANNE GRETE

Cardiologist, Senior Researcher, Leader Preventive Cardio-Rheuma Clinic, Chief CVD Reasearch Group, Diakonhjemmet Hospital, Oslo, Norway

SEN DWAIPAYAN

Consultant Stroke Phycisian, Comprehensive Stroke Centre, Alford Royal Hospital, Manchester, UK

SKENDROS PANAGIOTIS

Assistant Professor of Internal Medicine, Faculty of Medicine, Democritus University of Thrace, First Department of Internal Medicine, University Hospital of Alexandroupolis, Alexandroupolis, Greece

SKIADA ANNA

1 st Department of Propaedeutic Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece

SPELETAS MATTHAIOS

Associate Professor of Immunology. Department of Immunology and Histocompatibility, School of Health Sciences Faculty of Medicine, University of Thessaly, Larissa, Greece

TJWA ERIC

Department of Gastroenterology and Hepatology, Erasmus Medical Centre, Rotterdam, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands

SEVASTIANOS VASILEIOS

Physician in Internal Medicine and Hepatology, 4 Greece th Department of Internal Medicine, “Evangelismos” General Hospital, Athens, Greece

SFIKAKIS PETROS

Professor of Internal Medicine, Faculty of Medicine, University of Athens, Athens,

SIDERIS DIMITRIOS

Emeritus Professor of Cardiology, Faculty of Medicine, University of Ioannina, Athens, Greece

TOLIS CHRISTOS

Medical Oncology Specialist, Department of Medical Oncology, University General Hospital of Ioannina, Ioannina, Greece

TRIANTOS CHRISTOS

Gastroenterology Spesialist, Academic Department of Gastroenterology, University Hospital, Patras, Greece

TSELEPIS ALEXANDROS

Professor of Biochemistry-Clinical Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 71

INDEX OF INVITED FACULTY

TSIMIHODIMOS VASILEIOS

Assistant Professor of Internal Medicine, Medical School, University of Ioannina, Greece

TSIOUFIS KONSTANTINOS

Associate Professor of Cardiology, Faculty of Medicine, National & Kapodistrian University of Athens, Athens, Greece

VAN DER WORP BART

Neurologist, Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus,University Medical Centre Utrecht, Utrecht, The Netherlands

VELΤΚAMP ROLAND

Professor of Neurology, Chair of Stroke Medicine, Faculty of Medicine, Department of Medicine, Imperial College London, London, UK

VEMMOS KONSTANTINOS

Stroke Physician, President, Hellenic Stroke Organization, Athens, Greece

VERGANI DIEGO

Professor of Liver Immunopathology, Institute of Liver Studies, King's College Hospital, London, UK

VLAHAKOS DIMITRIOS

Professor of Medicine-Nephrology, Faculty of Medicine, National & Kapodistrian University of Athens, Director, Renal Unit, Attikon University General Hospital of Athens, Athens, Greece

72 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

INDEX OF ORAL & E-POSTER PRESENTATIONS

A

Adrian Parry-Jones Aggelakou-Vaitsi Stamatina Aggelidi Maria Aggelis Nikolaos Agrogianni Maria Akriviadis Evangelos OP05 e-PP54 e-PP53, e-PP67 e-PP52 e-PP25 OP10, OP11, OP20, e-PP14, e-PP15, e-PP21, e-PP22 Alaveras Antonios Al-Nofal Tzamal Alourda Foteini Alushi Evis e-PP39 e-PP50 e-PP89, e-PP90, e-PP91 e-PP78 Ameriso F. Sebastian Anagnostopoulou Evagelia OP04 OP25 Anastasakis Emmanouil e-PP35 Anastasiou Eustathia e-PP36, e-PP89, e-PP90 Angelidou Iliana Angelopoulou Stella-Maria Ansari Azhar Antypa Eleni Apostolidou Eirini Arabzadeh Nasereh Arampatzioglou Athanasios Arauz Antonio OP18 OP06 OP12 e-PP20 OP08 OP27 OP18 OP04 Arelaki Stella Armenis Iakovos Arnao Valentina Arvaniti Pinelopi OP08, OP18 OP34 OP04 OP13, OP14, OP15, OP16 Athanasakis George Athanasakis Kostas Athanasiadis Athanasios Athanasios Hastas Augoustaki Aikaterina OP04 e-PP16 OP32 e-PP23 OP21 Azariadi Kalliopi OP13, OP14, OP15, OP16, OP41

B

Baikoussis G. Nikolaos e-PP02, e-PP03 Bairaktari Eleni OP09, e-PP11 Bakarozi Marianna Bandini Fabio Banis Georgios e-PP88 OP04 e-PP60 Barboza A. Miguel Barka Melpomeni Bertsias Antonios Bitsikokou Athina OP04 e-PP52 OP21 OP35, e-PP42 Bjarnason Ingvar OP17 Bougias Dimitrios OP37, OP38, e-PP48, e-PP49, e-PP70, e-PP71, e-PP72, e-PP73, e-PP74, e-PP75, e-PP76 Boulbou Mary Bouliaris Konstantinos OP30, e-PP88 OP33 Bourdakis Adamantios Bouziana Stella Briasoulis Christos e-PP04 OP06 e-PP70, e-PP74

C

Cano Beatriz Chavarria CasMaurizio Paciaroni Valeria OP04 OP04 Cereda Carlo W. Chalevas Parthenis Chalmouki Panagiota Champakis Christos Chaniotakis Konstantinos OP01, e-PP06 OP03, OP10, OP11, e-PP14, e-PP15, e-PP22 e-PP39 e-PP18 Charalampous Charalampos Chartoumpekis Dionysios e-PP40, e-PP41 OP26, e-PP38 e-PP12 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 73

INDEX OF ORAL & E-POSTER PRESENTATIONS

Chatedaki Christina OP40 Chatzakis Christos Chia Liang Yoong e-PP09 Chatzimichael Eleftherios e-PP40, e-PP41 Chatzopoulos Kyriakos e-PP47, e-PP58, e-PP79, e-PP80, e-PP81, e-PP82, e-PP84 e-PP43 Chliara Maria OP26 Cholongitas Evangelos OP03, OP10, OP11, OP20, e-PP05, e-PP14, e-PP15, e-PP22 Chounta Athina Choutri Ekaterini e-PP16, e-PP17 e-PP45 Chrisostomou Evaggelia OP37, OP38, e-PP48, e-PP49, e-PP71, e-PP75, e-PP76 Christodoulidis Grigorios Christou Georgios Chrysanthos Nikolaos OP23, OP33 OP09 OP25 Chryssou Evaggelia Chung- Faye Guy Cuadrado-Godia Elisa e-PP29 OP17 OP04 Deliligka Aspasia Diakonikola Despoina Diamantidi Krystalia Diamantis Alexandros Diamantopoulou A. Diavasti Mariana Didaskalou Athanasios Diez-Tejedor Exuperio Dimas Grigorios Dimitriou Panagiotis Dimopoulos Evagelos Dokoutsidou Helen Dolgyras Stylianos Dontsos Christos Dougalis Apostolos e-PP07, e-PP59 OP03, e-PP05 Doulgeris Ioannis OP11, e-PP05 Doumtsis Petros OP03, OP20, e-PP15, e-PP22 Drakoulis Christos Droggoula Ourania Dubois Patrick e-PP47, e-PP58, e-PP79, e-PP80, e-PP81, e-PP82, e-PP84 OP24, e-PP36 e-PP39 OP23, OP33 OP20 OP11, OP03 OP35, e-PP42 OP04 OP36, e-PP01, e-PP09, e-PP10 OP06 e-PP83 e-PP83 e-PP07, e-PP50 e-PP18, e-PP19, e-PP25 e-PP69 OP17

D

Dalampira Christina Dalla Vasiliki Daskalogiannaki Maria David J Seiffge Dehghan Javid e-PP04 Dalekos George N. OP13, OP14, OP15, OP16,OP30, OP40, OP41, e-PP55, e-PP66, e-PP88 e-PP46 e-PP29 OP01 OP27

E

Eleftheriadou Athina Elisaf Moses Ellina Christina Eskandari Ashraf Etsuro Mori

F

Faliagkas Petros Familias Ioannis Farmaki Evangelia e-PP19, e-PP25 OP09, e-PP11 e-PP19, e-PP25 OP01 e-PP06 e-PP07 OP24 OP28 74 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

INDEX OF ORAL & E-POSTER PRESENTATIONS

Fasouloglou Athanasia e-PP48, e-PP49, e-PP72, e-PP73 Ferrari Julia Filippiadis Dimitris Finitsis Stefanos Florou Zoi Fouzas Ioannis Fuentes Blanca OP01, e-PP06 e-PP18 e-PP24 OP39, OP40 OP10 OP04

G

Gaitanaki Alexandra Galaktion Konstantinidis Galanakis Nikolaos e-PP50 OP36 OP22 Galliopoulos Demos Garyfallos Alexandros e-PP44 OP03, e-PP05 Gatsa Eleni e-PP85 Gatselis Nikolaos OP13, OP14, OP15, OP16, OP30, OP41, e-PP55 Gavriilaki Eleni e-PP07, e-PP37, e-PP50, e-PP59 Georgiadis Thomas Georgiadou Sara OP30, OP41, e-PP66 Georgiou Christos e-PP64 OP38, e-PP48, e-PP49, e-PP71, e-PP75, e-PP76 Georgiou Fotini Georgopoulos Ilias Germenis E. Anastasios Ghasemi Hadi Pordel e-PP45 e-PP33, e-PP61, e-PP63, e-PP65 OP28, OP29 OP27 Giampatzis Vasilios OP06 Gianniki Maria OP37, OP38, e-PP48, e-PP49, e-PP70, e-PP71, e-PP72, e-PP73, e-PP74, e-PP75, e-PP76 Giatromanolaki Alexandra OP18, e-PP46 Giatroudakis Konstantinos e-PP40, e-PP41 Gil-Núñez Antonio OP04 Gioulekas Fotios Giovannopoulou Eirini e-PP40, e-PP41 Giralt-Steinhauer Eva OP02 OP04 Gkantsinikoudis Nikolaos Gkasdaris Grigorios e-PP40, e-PP41 e-PP40, e-PP41 Gkeka O. OP20 Gkogkos Georgios e-PP69, e-PP86 Gkountouras Georgios e-PP34, e-PP52, e-PP60 Glynos Constantinos Gómez-Schneider Maia Goudevenos John OP31 OP04 OP09 Goulis Ioannis OP10, OP11, OP20, e-PP14, e-PP15, e-PP22 Gouloumi Alina - Roxani e-PP18 Grekas Dimitrios Guillaud Constance e-PP01, e-PP10 e-PP57 Gulati Shraddha OP17

H

Habeos Ioannis Hahalis Georgios Harxhi Arjan Hastas Athanasios Hayee Bu’Hussain e-PP12 e-PP47, e-PP58, e-PP79, e-PP80, e-PP82, e-PP84 e-PP77 OP24, e-PP36 Hatzidakis Adam Hawkes A. Maximiliano OP22, e-PP29 Hatzitolios Apostolos OP06, OP36, e-PP01, e-PP09, e-PP10, e-PP26 Hatzopoulos Andreas e-PP33, e-PP63, e-PP65 OP04 OP17 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 75

INDEX OF ORAL & E-POSTER PRESENTATIONS

76 Heo Ji Hoe Hera M. Heras Panagiotis Heydari Zahra Hyatt Raymond Hytiroglou Prodromos OP01, e-PP06 e-PP63 e-PP33, e-PP61, e-PP63, e-PP65 OP27 e-PP51 e-PP21

I

Iglesias Mohedano Ana Maria Ioannidou Anastasia OP04 e-PP19, e-PP25 Ioannidou Maria Ioannis Familias e-PP14, e-PP22 e-PP23 Ioannou Maria Ischaki Eleni OP32 OP31

K

Kakaletsis Nikolaos Kakkas Ioannis Kakouris Georgios e-PP06 OP28 e-PP02, e-PP03 Kalafateli Maria Kalaitzoglou Asterios OP19, e-PP29 e-PP37 Kalantzis Konstantinos e-PP68 Kaliotzoglou Anastasia e-PP89, e-PP90, e-PP91 Kaliouli-Antonopoulou Christiana e-PP17, e-PP25 Kalliakmanis Andreas Kalotychou Vasiliki OP35, e-PP42 Kalliara Anastasia Theodora e-PP86 Kalogiannis Evangelos e-PP08, e-PP32 OP34 Kalra Kavita Kambas Konstantinos Kapanidis Konstantinos e-PP56 OP08, OP18 OP36 Kapatais Α. e-PP30, e-PP31 Kapatou Kassiani Kapetanakis Stylianos e-PP40, e-PP41 Kapoussouzi Androniki OP32 OP28 Kapros Elias Kapsoritakis Andreas e-PP53, e-PP67, e-PP87 OP32 Karageorgos Charalampos Karakousis Konstantinos Karamagkiolis Spiridon Karamanli Κ. e-PP85, e-PP68 e-PP60 e-PP34 e-PP30, e-PP31 Karamitsos Konstantinos e-PP34, e-PP52, e-PP60 Karamouzis Ioannis Karampampa Christina Karaoulani Theofania e-PP01, e-PP09, e-PP10 e-PP19, e-PP30, e-PP31 Karasavidou Larisa Karasmani Areti Karatapanis Stylianos Karavana Vassiliki e-PP19, e-PP25 OP20 OP24, e-PP23, e-PP35, e-PP36, e-PP89, e-PP90, e-PP91 OP31 Karavidas Nikitas Karnesis Lazaros Karvouniaris Nikolaos Kastani Ioanna Katagis George Katsarou Irene Katsilis Nikitas Katsiva Vasiliki Kehagias Elias Keramidas Angelos Ketikoglou Ioannis Khazaei Ali Hossein Khazaei Amin Khazaei Ehsan Kitsou Sotiria Kokalis Christos Kokkoris Stelios e-PP69, e-PP86 e-PP20, e-PP64 e-PP35 OP09 e-PP72, e-PP73 e-PP67 OP24, e-PP36, e-PP89, e-PP91 e-PP18 OP22, e-PP29 OP26, e-PP38 e-PP27, e-PP28 OP27 OP27 OP27 e-PP70, e-PP74 e-PP18 e-PP18 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

INDEX OF ORAL & E-POSTER PRESENTATIONS

Kolotsiou Aikaterini OP11, e-PP05 Konstantinides Stavros Konstantinidis Theocharis OP08 OP08 Konstantopoulos Konstantinos Konstantoula Theodora e-PP52, e-PP60 Kontogeorgiou Zoe OP34 OP34 Kontoriga Ekaterini Korkolopoulou Pinelopi Koroboki Elena e-PP18, e-PP19, e-PP25 OP25 OP04 Kostaki Stavroula Kostara Christina Kotoula Paraskevi Kotsianidis Ioannis Koufomichali Xanthi Koukoulis George K. Koulara Pavlina Koulentaki Meri Koulias Emmanuel Koumoutsou Flora Kouroumalis A. Elias Kourousis Dimitrios OP06 OP09, e-PP11 e-PP44 e-PP46 e-PP19 OP13, OP14, OP32, e-PP55 e-PP26 OP21, OP22 e-PP27 e-PP34 OP21, OP22, e-PP29 e-PP19 Koutroubi Maria Koutsoukis Athanasios e-PP33, e-PP61, e-PP63, e-PP65 e-PP57 Krapis Konstantinos Kurniawan Mohammad OP01, e-PP06 Kyriakos Nikolaos e-PP34, e-PP52, e-PP60 e-PP20 Kyriazopoulou Venetsanea Kyritsis Antonis OP19 e-PP27

L

Lachanis Stefanos Lalos Vasileios Lalou Polyxeni e-PP20 e-PP52 OP30 Lamprianou Foteini Lapis Ioannis Larissi Maria Lascu Georgeta Laspa Christina Laspa Eugenia Lavdaniti Maria Lee Jia Wern Lees R Kennedy Lefaki Ioanna Lialios Georgios Liatsos Christos Liougka Evaggelia Lip Y.H. Gregory Lo Francis Loizou Areti Lolos Ioannis Lucas Josefa Pérez Lucas Zarah Luci Rozeta Lygdi Loukia Lygoura V. OP24, e-PP35, e-PP91 e-PP89, e-PP90, e-PP91 OP36, e-PP09 e-PP57 e-PP08, e-PP32 e-PP08, e-PP32 e-PP62, e-PP83 e-PP43 OP01, e-PP06 e-PP46 e-PP44 e-PP20 e-PP07, e-PP50 OP04 e-PP43 e-PP13, e-PP45 e-PP68, e-PP85 OP04 e-PP56 e-PP77, e-PP78 e-PP05 OP13, OP14

M

Magkou Christina Makaritsis Konstantinos Malachias Sotirios Malamati Vreka Malli Ergina Mandala Evdokia Manika Kleanthi Manios Efstathios Manoulakas E. Margaritis Athanasios Margonis Euaggelos OP31 OP04, OP30, e-PP66 OP31 OP31 OP39 OP03, e-PP05 e-PP15 OP01, OP04, e-PP06 e-PP66 OP37 OP33 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 77

INDEX OF ORAL & E-POSTER PRESENTATIONS

Marias Mihail e-PP23, e-PP36, e-PP89, e-PP90, e-PP91 Maritsa Dimitra Markantonatou A.M. e-PP68, e-PP85 OP20 Maroulakou Ioanna Matrella Erminia Matsagas Miltiadis Mauraki Eugenia Mavrantoni Evi Mavridis Giorgos Mavromanoli Anna Mechmet Sadi Melios Achileas Mentzelopoulos Spyros Michalaki Marina Michel Patrik Michelakis Evangelos Miftari Brunilda Milonas Stefanos Miltiades Paraskevi Mironidou-Tzouveleki Maria OP18 OP21, OP22 e-PP02 e-PP87 OP36 OP26, e-PP38 e-PP01 e-PP46 OP25 OP31 OP19 OP01, OP02, e-PP06 e-PP25 e-PP77 e-PP68, e-PP85 OP18 e-PP08, e-PP32 Mitroulis Ioannis OP08 Mitsios Alexandros Mitsis Christos Molloy Jane Mori Etsuro Moschouris Hipocrates Mosheta Eleni Moulin Solène Mouzaki Athanasia Mouzas Ioannis Mpika Spiridoula Mpiternas Michalis Mpoumpas Dimitrios OP18 OP37, OP38, e-PP70, e-PP74 OP05 OP01 e-PP53, e-PP87 e-PP72, e-PP73 OP01, e-PP06 OP19 OP22, e-PP29 e-PP69, e-PP86 e-PP50 e-PP16

N

Nakopoulou Fani Nakuci Mikel Neokleous Nikolaos Neokosmidis Georgios Niarchos Athanasios Nikaj Sonila Nikitas Katsilis Nikolaidou Christina e-PP69 e-PP77 e-PP45 e-PP24, e-PP26 e-PP12 e-PP78 e-PP23 e-PP47, e-PP58, e-PP79, e-PP80, e-PP81, e-PP82, e-PP84 Nikolaou Vasilios Ntaios George e-PP19 OP01, OP02, OP04, e-PP06, e-PP66 Nteik El Elina e-PP27, e-PP28 Ntetskas Georgios OP24, e-PP23, e-PP35, e-PP36, e-PP89, e-PP90, e-PP91

O

Oikonomou Dimitris Oikonomou Theodora Orfanoudaki Elina Orologas Anastasios

P

Paellas Chrysostomos Palazis Lakis Paliouras Christos Panayiotides Ioannis Pantos Konstantinos Papadaki Sotiria Papadamou G. Papadatos Stamatis e-PP85 OP10, e-PP15 OP21 OP36 e-PP23 e-PP13, e-PP45 e-PP35 e-PP18 OP34 e-PP27, e-PP28 OP13, e-PP66 e-PP04 78 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

INDEX OF ORAL & E-POSTER PRESENTATIONS

Papadatou Aggeliki e-PP53, e-PP67, e-PP87 Papadimitropoulos George e-PP17 Papadopoulos Georgios Papadopoulos Nikolaos e-PP02 e-PP20, e-PP64 Papadopoulos S. Georgios e-PP03 Papadopoulou Apostolina OP37, OP38, e-PP48, e-PP49, e-PP71, e-PP73, e-PP75, e-PP76 Papadopoulou Maria Papadopoulou Stauroula OP06 e-PP47, e-PP58, e-PP79, e-PP80, e-PP81, e-PP82, e-PP84 Papageorgiou Chrysoula Papageorgiou Lampros Papagiannis Achilleas Papagoras Charalampos OP26 e-PP70, e-PP71, e-PP74, e-PP75 e-PP24 e-PP46 Papaioannou Georgios Papakonstantinou Anna Papakosta Styliani Papamichali Roidoula e-PP37, e-PP59 e-PP08, e-PP32 e-PP44 OP32 Papanastasiou Α. Papandreou Christos Papanikolaou Nikolaos Papanikolaou Vasilios e-PP30, e-PP31 OP32 e-PP07 OP10 Papastergiou Kerasina Papastergiou Vasilios e-PP62, e-PP83 OP24, e-PP36, e-PP90, e-PP91 Papathanasiou Maria Papavasileiou Vasileios OP01, OP02, OP04, OP05, e-PP06, e-PP51 Papiamonis Nikolaos OP32 e-PP29 Pappas Efthimios Parasyris Vassilios Parthenis Chalevas Paschou Eleni e-PP37, e-PP59 e-PP64 e-PP05 e-PP07, e-PP37, e-PP50, e-PP59 Pastor Andrés García Patouras Paraskeyas Patsavela Stamatia Pavlidis Polychronis OP04 e-PP64 OP25 OP12, OP17 Pavlopoulos Konstantinos Pavlou Μ. e-PP09 e-PP30, e-PP31 Perivoliotis Konstantinos Pertierra Lucía OP23, OP33 OP04 Petinaki Efthymia Petrou Danae Pirou Nikoleta Pliarchopoulou Fani OP39, OP40, OP41 OP26 e-PP01 e-PP16, e-PP17 Polychronopoulou Erietta Polyzos Asterios OP33 e-PP88 Potamianos Spyros Pournou Anastasia OP32 OP37, OP38, e-PP48, e-PP49, e-PP70, e-PP71, e-PP72, e-PP73, e-PP74, e-PP75, e-PP76 Protopapas Andreas Psellakis Georgios Psyrri Adamantia Putaala Jukka e-PP24, e-PP26 e-PP89 e-PP18 OP04

Q

Quah Teik Joo e-PP43 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 79

INDEX OF ORAL & E-POSTER PRESENTATIONS

80

R

Raw Jason Rigopoulou Eirini I. OP07 OP13, OP30, e-PP88 Ritis Konstantinos OP08, OP18, e-PP46 Rodríguez-Campello Ana OP04 Rombos Ioannis Rontogianni Dimitra Rostami Amin Roufas Konstantinos Rountas Christos OP34 e-PP20 OP27 OP24, e-PP23, e-PP35, e-PP36 e-PP55

S

Sabanis Nikos Samakidou Georgia Samara Maria Samara Vasiliki Samaras Athanasios Samonakis Dimitrios N. Saravanon N Sarrou Styliani Savopoulos Christos Seiffge J David Selfo Denada Sen Dwaipayan Sevdali Eirini Sfendouraki Elissavet Sherwood Roy Shi Yue Sideri E. e-PP07, e-PP37, e-PP50, e-PP59 e-PP52, e-PP60 OP32 e-PP85 e-PP10 OP19, OP21, OP22, e-PP29 OP07 OP39, OP40 OP06, OP36, e-PP01, e-PP09, e-PP10 e-PP06 e-PP77 OP07, e-PP51 OP28 OP35, e-PP42 OP17 e-PP56 e-PP30, e-PP31 Sidiropoulos Orestis e-PP17 Siminelakis Stavros N. Sinakos Emmanouil Sinanaj Glodiana Sindhu Kaniz Rabia Skendros Panagiotis Skorda Lamprini Skoufi Georgia Solomou S. e-PP02, e-PP03 e-PP21 e-PP77 OP05 OP08, OP18, e-PP46 e-PP39 e-PP44 e-PP30, e-PP31 Song Tae-Jin OP01, e-PP06 Soulaidopoulos Stergios OP03, OP10, OP11, OP20, e-PP05, e-PP14, e-PP15, e-PP22 Spadidea Panagiota Spagos Georgios Spanou Marianna Speletas Matthaios OP19 e-PP10 OP06 OP28, OP29, e-PP46 Spiroglou Sofia Spirou Antigoni Stakos Dimitrios e-PP01, e-PP09, e-PP10 e-PP01, e-PP10 Stamatopoulos Alexandros OP08 e-PP14, e-PP22 Stamatopoulos Theodosis Stampori Maria e-PP14, e-PP22 OP24, e-PP23, e-PP36, e-PP89, e-PP90, e-PP91 Stathopoulos George Stavropoulou Ε. OP31 e-PP30, e-PP31 Stefanopoulos Anastasios e-PP33, e-PP61, e-PP63, e-PP65 Stefanou Christos e-PP13, e-PP45 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

INDEX OF ORAL & E-POSTER PRESENTATIONS

Stefos Aggelos OP30, OP40, e-PP88 Stogianni Aikaterini Stogianni Eleftheria e-PP44 e-PP44 Stournaras Evangelos e-PP24, e-PP26 Stragalis Christos-Panagiotis e-PP10 Strbian Daniel Stylianidis Stylianos OP01, OP02, e-PP06 e-PP24, e-PP26 Subashi Brunilda Subashi Llambi Syeda Aisha Iftikhar Syrmou Vasiliki e-PP78 e-PP77 OP05 e-PP55

T

Taparkou Anna Tatlisumak Turgut Tatsina Eirini Tegos Thomas OP28 OP01, OP04, e-PP06 OP37, OP38, e-PP48, e-PP49, e-PP70, e-PP71, e-PP72, e-PP73, e-PP74, e-PP75, e-PP76 OP36 Tepetes Konstantinos Theodoraki Eirini Theodorou Ioannis Theodoroula Efterpi OP23, OP33 OP21, e-PP29 e-PP46 e-PP68, e-PP85 Thomopoulos Konstantinos Timiliotou Chrystalla OP19 e-PP13, e-PP45 Tolis Konstantinos Toska Triantafyllia Triantafyllou Ourania e-PP72, e-PP73 e-PP39 e-PP34, e-PP52, e-PP60 Triantaris Apostolos Triantos Christos e-PP44 OP19 Tsagkarousianos Christos e-PP53, e-PP67, e-PP87 Tsaitas Christos e-PP21 Tsekeri Maria e-PP39 Tsetis Dimitrios Tsiabalis Athanasios Tsiafoulis Kostas Tsiampalis Athanasios OP22, e-PP29 e-PP85 OP09, e-PP11 e-PP68 Tsiaras Nikolaos Tsifetaki Niki Tsimihodimos Vasileios Tsinti Gerasimina OP36, e-PP01 OP37, OP38, e-PP48, e-PP49, e-PP70, e-PP71, e-PP72, e-PP74, e-PP75, e-PP76 OP09, e-PP11 OP29 Tsionara Dimitra Tsitsia Maria Tsolakidou Charikleia Tsompanakou Aliki Tsotsiou Eleni Turecky Ladislav Tyrrell J. Pippa Tzanetea Reveka Tzardi Maria Tziomalos Konstantinos Tziortziotis Apostolos e-PP34, e-PP52, e-PP60 e-PP55 e-PP07, e-PP50 e-PP37 e-PP07, e-PP50 e-PP09 OP05 OP34 OP21, e-PP29 OP06 e-PP86 Tzortzi Christiana Tzovaras Georgios e-PP45 OP23

U

Uranou Ε. e-PP30, e-PP31

V

Vagdatli E. Vaitsi Konstantina Vaitsis Nikolaos Valais Sotirios OP20 OP03, OP11 e-PP54 e-PP44 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 81

INDEX OF ORAL & E-POSTER PRESENTATIONS

82 Valari Zoi OP10 Varsamis Nikolaos Vasileiadis Panagiotis Vasileiou Sotirios Vasiliadis Themistoklis Vasilios Papastergiou Vemmos Konstantinos Vemmou Anastasia Venizelos Ioannis e-PP76 e-PP38, OP26 e-PP59 OP10 e-PP23 OP01, OP04, e-PP06 OP04 e-PP47, e-PP58, e-PP79, e-PP80, e-PP81, e-PP82, e-PP84 Verra Chrysoula Vetas Christos e-PP02, e-PP03 e-PP14, e-PP15 Vetsiou Evangelia OP11, e-PP14, e-PP15, e-PP22 Vettas Christos Voukelatou Panagiota Voulgaridi Ioanna Voumvourakis Konstantinos Vrettos Ioannis OP40 e-PP17 OP35, e-PP42 Vrettou S. Charikleia OP03, e-PP05 OP35, e-PP42 OP31

W

Weder Bruno J. Weimar Christian OP01, e-PP06 OP01, e-PP06

Y

Yan Bernard OP01, e-PP06

Z

Zacharoulis Dimitrios Zachou Kalliopi OP23 OP13, OP14, OP15, OP16, OP41, e-PP55 Zahaj Majlinda e-PP78 Zaharis Georgios e-PP90 Zakynthinos Spyros Zioganas Vassilios Zissis Christos Zormpas Aggelos OP31 e-PP21 e-PP68, e-PP85 e-PP69, e-PP86 Zotos Nikolaos Zoumbouli Christina OP37, OP38, e-PP48, e-PP49, e-PP70, e-PP71, e-PP72, e-PP73, e-PP74, e-PP75, e-PP76 e-PP28 Zyga Sofia e-PP62, e-PP83 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

SPONSORS/ACKNOWLEDGEMENTS

The Organizing Committee of the Congress would like to express their sincere thanks to the following companies for their financial support and contribution to the accomplishment of this Congress:

PLATINUM SPONSORS GOLD SPONSORS SILVER SPONSORS SPONSORS

K O P O U L

The Organizing Committee would also like to thank the Regional Association of Thessaly municipalities for their kind support to this year’s organization.

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 83

FLOOR PLAN (HALL)

HALL ACHILLEAS Oral Presentations RESTAURANT LOBBY EXHIBITION HALL MAIN HALL OLYMPOS Main Hall Oral Presentations e-Poster Presentations • • • • • HALL • Olympos Olympos Achilleas Chrisalida Alkistis - Thetida Nefeli FOYER SECRETARIAT HALL NEFELI e-Poster Presentations HALL ALKISTIS-THETIDA e-Poster Presentations HALL CHRISALIDA e-Poster Presentations 84 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

NOTES

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 85

NOTES

86 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

NOTES

8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece 87

NOTES

88 8 th Larissa International Congress of Internal Medicine, March 17-19, 2016, Larissa, Greece

1 ÅÔ

ÄϾÊʹÔ

κινηθείτε ελεύθερα ΣΤΟ ΝΕΟ ΜΟΝΟΠΑΤΙ ο πρώτος και ο µοναδικός εγκεκριµένος αναστολέας IL-17A

Έως και 80% των ασθενών με ΑΣ (αγκυλοποιητική σπονδυλίτιδα) που έλαβαν θεραπεία με

COSENTYX

δεν εμφάνισαν επιδείνωση της βλάβης της σπονδυλικής στήλης σύμφωνα με μετρήσεις μέσω ακτινογραφιών σε διάστημα δύο ετών.

1 Έως και 84% των ασθενών με ΨΑ (ψωριασικά αρθρίτιδα) που έλαβαν θεραπεία με δύο ετών.

2

COSENTYX

δεν εμφάνισαν επιδείνωση της βλάβης των αρθρώσεων στις ακτινογραφίες σε διάστημα Αγκυλοποιητική σπονδυλίτιδα Το Cosentyx ενδείκνυται για τη θεραπεία της ενεργού αγκυλο ποιητικής σπονδυλίτιδας σε ενήλικες οι οποίοι δεν έχουν αντα ποκριθεί επαρκώς στη συμβατική θεραπεία.

3 Ψωριασική αρθρίτιδα Το Cosentyx, σε μονοθεραπεία ή σε συνδυασμό με μεθοτρεξάτη (ΜΤΧ), ενδείκνυται για τη θεραπεία της ενεργού ψωριασικής αρθρίτιδας σε ενήλικες ασθενείς όταν η ανταπόκριση σε προηγούμενη θεραπεία με τροποποιητικό της νόσου αντιρευματικό φάρμακο (DMARD) δεν ήταν επαρκής.

3

Βιβλιογραφία 1.

Baraliakos X, Deodhar A, Braun J et al. Effect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab. Late breaking abstract presented at the 2015 ACR/ARHP Annual Meeting, San Francisco, USA, November 10. Oral presentation, abstract number: 6L (ACR 2015 abstract book)

2.

3.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab provides sustained improvements in psoriatic arthritis: 2-year efficacy and safety results from a phase 3 randomized, double-blind, placebo-controlled trial. Presented at the 2015 ACR/ARHP Annual Meeting, San Francisco, USA, November 9. Oral presentation, abstract number: 2148 (ACR 2015 abstract book). Cosentyx Περίληψη Χαρακτηριστικών του Προιόντος, Νοέμβριος 2015 EUROPEAN MEDICINES AGENCY S C I E N C E M E D I C I N E S H E A L T H

ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

W Το φάρµακο αυτό τελεί υπό συµπληρωµατική παρακολούθηση. Αυτό θα επιτρέψει τον ταχύ προσδιορισµό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελµατίες του τοµέα της υγειονοµικής περίθαλψης να αναφέρουν οποιεσδήποτε πιθανολογούµενες ανεπιθύµητες ενέργειες. Βλ. παράγραφο 4.8 για τον τρόπο αναφοράς ανεπιθύµητων ενεργειών.

1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ Cosentyx 150 mg ενέσιµο διάλυµα σε προγεµισµένη συσκευή τύπου πένας. Cosentyx 150 mg ενέσιµο διάλυµα σε προγεµισµένη σύριγγα 2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ Κάθε προγεµισµένη συσκευή τύπου πένας περιέχει 150 mg secukinumab σε 1 ml. Κάθε προγεµισµένη σύριγγα περιέχει 150 mg secukinumab σε 1 ml. *Το secukinumab είναι ένα ανασυνδυασµένο πλήρως ανθρώπινο µονοκλωνικό αντίσωµα εκλεκτικό για την ιντερλευκίνη 17A. Το secukinumab ανήκει στην IgG1/κ κατηγορία και παράγεται σε κύτταρα Ωοθηκών Κινεζικού Κρικητού (CHO). Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. 3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ Ενέσιµο διάλυµα σε προγεµισµένη συσκευή τύπου πένας (πένα SensoReady). Ενέσιµο διάλυµα σε προγεµισµένη σύριγγα (ένεση). Το διάλυµα είναι διαυγές και άχρωµο έως ελαφρώς κίτρινο. 4. ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ 4.1 Θεραπευτικές ενδείξεις Ψωρίαση κατά πλάκας. Το Cosentyx ενδείκνυται για τη θεραπεία της µέτριας έως σοβαρής ψωρίασης κατά πλάκας σε ενήλικες οι οποίοι είναι υποψήφιοι για συστηµατική θεραπεία. Ψωριασική αρθρίτιδα Το Cosentyx, σε µονοθεραπεία ή σε συνδυασµό µε µεθοτρεξάτη (ΜΤΧ), ενδείκνυται για τη θεραπεία της ενεργού ψωριασικής αρθρίτιδας σε ενήλικες ασθενείς όταν η ανταπόκριση σε προηγούµενη θεραπεία µε τροποποιητικό της νόσου αντιρευµατικό φάρµακο (DMARD) δεν ήταν επαρκής (βλ. παράγραφο 5.1). Αγκυλοποιητική σπονδυλίτιδα Το Cosentyx ενδείκνυται για τη θεραπεία της ενεργού αγκυλοποιητικής σπονδυλίτιδας σε ενήλικες οι οποίοι δεν έχουν ανταποκριθεί επαρκώς στη συµβατική θεραπεία. 4.2 ∆οσολογία και τρόπος χορήγησης Το Cosentyx προορίζεται για χρήση υπό την καθοδήγηση και την επίβλεψη ιατρού µε εµπειρία στη διάγνωση και τη θεραπεία των νοσηµάτων για τα οποία ενδείκνυται το Cosentyx. ∆οσολογία Ψωρίαση κατά πλάκας Η συνιστώµενη δόση είναι 300 mg secukinumab µε υποδόρια ένεση µε αρχική χορήγηση της δόσης τις Εβδοµάδες 0, 1, 2 και 3, ακολουθούµενη από µηνιαία δόση συντήρησης µε έναρξη την Εβδοµάδα 4. Η κάθε δόση των 300 mg χορηγείται ως δύο υποδόριες ενέσεις των 150 mg. Ψωριασική αρθρίτιδα Για τους ασθενείς µε συνυπάρχουσα µέτρια έως σοβαρή ψωσίαση κατά πλάκας ή που έχουν ανεπαρκή ανταπόκριση σε αντι-TNFα (ΙR), η συνιστώµενη δόση είναι 300 mg µε υποδόρια ένεση και αρχική χορήγηση τις Εβδοµάδες 0, 1, 2 και 3, ακολουθούµενη από µηνιαία δοσολογία συντήρησης που ξεκινάει την Εβδοµάδα 4. Κάθε δόση των 300 mg χορηγείται ως δύο υποδόριες ενέσεις των 150 mg. Για τους άλλους ασθενείς, η συνιστώµενη δόση είναι 150 mg µε υποδόρια ένεση και αρχική χορήγηση τις Εβδοµάδες 0,1,2 και 3, ακολουθούµενη από δοσολογία συντήρησης µε µηνιαία χορήγηση που ξεκινάει την Εβδοµάδα 4. Αγκυλοποιητική σπονδυλίτιδα Η συνιστώµενη δόση είναι 150 mg µε υποδόρια ένεση και αρχική χορήγηση τις Εβδοµάδες 0, 1, 2 και 3, ακολουθούµενη από δοσολογία συντήρησης µε µηνιαία χορήγηση που ξεκινάει την Εβδοµάδα 4. Για όλες τις παραπάνω ενδείξεις, τα διαθέσιµα δεδοµένα υποδηλώνουν ότι η κλινική ανταπόκριση επιτυγχάνεται συνήθως εντός 16 εβδοµάδων θεραπείας. Θα πρέπει να εξετάζεται το ενδεχόµενο διακοπής της θεραπείας σε ασθενείς οι οποίοι δεν έχουν εµφανίσει ανταπόκριση µετά από θεραπεία έως και 16 εβδοµάδων. Ορισµένοι ασθενείς µε αρχική µερική ανταπόκριση πιθανόν να εµφανίσουν στη συνέχεια βελτίωση µε συνέχιση της θεραπείας πέραν των 16 εβδοµάδων. Ειδικοί πληθυσµοί

Ηλικιωµένοι ασθενείς (ηλικίας 65 ετών και άνω)

∆εν απαιτείται προσαρµογή της δόσης (βλ. παράγραφο 5.2).

Νεφρική δυσλειτουργία / ηπατική δυσλειτουργία

Το Cosentyx δεν έχει µελετηθεί σε αυτούς τους πληθυσµούς ασθενών. ∆εν µπορούν να γίνουν συστάσεις για τη δοσολογία.

Παιδιατρικός πληθυσµός

Η ασφάλεια και αποτελεσµατικότητα του Cosentyx σε παιδιά ηλικίας κάτω των 18 ετών δεν έχουν ακόµα τεκµηριωθεί. ∆εν υπάρχουν διαθέσιµα δεδοµένα. Τρόπος χορήγησης Το Cosentyx πρέπει να χορηγείται µε υποδόρια ένεση. Εάν είναι εφικτό, οι περιοχές του δέρµατος που εµφανίζουν ψωρίαση θα πρέπει να αποφεύγονται ως σηµεία της ένεσης. Μετά από κατάλληλη εκπαίδευση στην τεχνική της υποδόριας ένεσης, οι ασθενείς ενδέχεται να κάνουν µόνοι τους την ένεση του Cosentyx, εάν ο ιατρός κρίνει ότι αυτό είναι κατάλληλο. Ωστόσο, ο ιατρός θα πρέπει να διασφαλίσει την κατάλληλη παρακολούθηση των ασθενών. Οι ασθενείς θα πρέπει να λάβουν οδηγίες ώστε να ενίουν την πλήρη ποσότητα του Cosentyx σύµφωνα µε τις οδηγίες που παρέχονται στο φύλλο οδηγιών χρήσης. Αναλυτικές οδηγίες σχετικά µε τη χορήγηση παρέχονται στο φύλλο οδηγιών χρήσης. 4.3 Αντενδείξεις Σοβαρές αντιδράσεις υπερευαισθησίας στη δραστική ουσία ή σε κάποιο από τα έκδοχα που αναφέρονται στην παράγραφο 6.1. Κλινικά σηµαντική, ενεργός λοίµωξη (π.χ. ενεργός φυµατίωση, βλ. παράγραφο 4.4). 4.4 Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση Λοιµώξεις Το Cosentyx δυνητικά µπορεί να αυξήσει τον κίνδυνο των λοιµώξεων. Στις κλινικές µελέτες, έχουν παρατηρηθεί λοιµώξεις σε ασθενείς που λαµβάνουν Cosentyx (βλ. παράγραφο 4.8) Οι περισσότερες από αυτές ήταν ήπιες ή µέτριας βαρύτητας λοιµώξεις της ανώτερης αναπνευστικής οδού, όπως ρινοφαρυγγίτιδα, και δεν έχρηζαν διακοπής της θεραπείας. Σχετιζόµενες µε τον µηχανισµό δράσης του Cosentyx, µη-σοβαρές βλεννογονοδερµατικές καντιντιασικές λοιµώξεις αναφέρθηκαν πιο συχνά µε το secukinumab απ’ ότι µε το εικονικό φάρµακο στις κλινικές µελέτες της ψωρίασης (3,55 ανά 100 έτη ασθενών για το secukinumab 300 mg έναντι 1,00 ανά 100 έτη ασθενών για το εικονικό φάρµακο) (βλ. παράγραφο 4.8). Απαιτείται προσοχή όταν εξετάζεται το ενδεχόµενο χρήσης του Cosentyx σε ασθενείς µε χρόνια λοίµωξη ή ιστορικό υποτροπιάζουσας λοίµωξης. Στους ασθενείς θα πρέπει να δίνονται οδηγίες να ζητούν ιατρική συµβουλή σε περίπτωση εµφάνισης σηµείων ή συµπτωµάτων που υποδηλώνουν λοίµωξη. Εάν ο ασθενής αναπτύξει σοβαρή λοίµωξη, θα πρέπει να παρακολουθείται στενά και το Cosentyx δεν θα πρέπει να χορηγείται µέχρι την αποδροµή της λοίµωξης. ∆εν αναφέρθηκε αυξηµένη ευαισθησία στη φυµατίωση στις κλινικές µελέτες. Ωστόσο, το Cosentyx δεν θα πρέπει να χορηγείται σε ασθενείς µε ενεργό φυµατίωση. Θα πρέπει να εξετάζεται το ενδεχόµενο χορήγησης αντι-φυµατικής θεραπείας πριν από την έναρξη του Cosentyx στους ασθενείς µε λανθάνουσα φυµατίωση. Νόσος του Crohn Απαιτείται προσοχή όταν το Cosentyx συνταγογραφείται σε ασθενείς µε νόσο του Crohn καθώς παρατηρήθηκαν εξάρσεις της νόσου του Crohn, οι οποίες σε ορισµένες περιπτώσεις ήταν σοβαρές, σε κλινικές µελέτες τόσο στην οµάδα του Cosentyx όσο και στην οµάδα του εικονικού φαρµάκου. Οι ασθενείς, οι οποίοι λαµβάνουν θεραπεία µε Cosentyx και έχουν νόσο του Crohn θα πρέπει να παρακολουθούνται στενά. Αντιδράσεις υπερευαισθησίας Στις κλινικές µελέτες, έχουν παρατηρηθεί σπάνιες περιπτώσεις αναφυλακτικών αντιδράσεων σε ασθενείς υπό θεραπεία µε Cosentyx. Σε περίπτωση αναφυλακτικής αντίδρασης ή άλλων σοβαρών αλλεργικών αντιδράσεων, η χορήγηση του Cosentyx πρέπει να διακοπεί αµέσως και να ξεκινήσει κατάλληλη αγωγή. Άτοµα ευαίσθητα στο Λάτεξ Το αφαιρούµενο καπάκι της προγεµισµένης πένας του Cosentyx περιέχει ένα παράγωγο του φυσικού ελαστικού λάτεξ. ∆εν έχει ανιχνευθεί µέχρι σήµερα φυσικό ελαστικό λάτεξ στο αφαιρούµενο καπάκι. Ωστόσο, η χρήση των προγεµισµένων συσκευών τύπου πένας του Cosentyx σε άτοµα ευαίσθητα στο λάτεξ δεν έχει µελετηθεί και εποµένως υπάρχει δυνητικός κίνδυνος αντιδράσεων υπερευαισθησίας ο οποίος δεν µπορεί να αποκλεισθεί εντελώς. Το αφαιρούµενο καπάκι της βελόνας της προγεµισµένης σύριγγας του Cosentyx περιέχει ένα παράγωγο του φυσικού ελαστικού λάτεξ. ∆εν έχει ανιχνευθεί µέχρι σήµερα φυσικό ελαστικό λάτεξ στο αφαιρούµενο καπάκι της βελόνας. Ωστόσο, η χρήση των προγεµισµένων συρίγγων του Cosentyx σε άτοµα ευαίσθητα στο λάτεξ δεν έχει µελετηθεί και εποµένως υπάρχει δυνητικός κίνδυνος αντιδράσεων υπερευαισθησίας ο οποίος δεν µπορεί να αποκλεισθεί εντελώς. Εµβολιασµοί Εµβόλια µε ζώντες µικροοργανισµούς δεν θα πρέπει να χορηγούνται ταυτόχρονα µε το Cosentyx. Οι ασθενείς που λαµβάνουν Cosentyx µπορούν ταυτόχρονα να εµβολιασθούν µε εµβόλια αδρανοποιηµένων ή µη ζώντων µικροοργανισµών. Σε µία µελέτη, µετά από εµβολιασµούς µε µηνιγγιτιδόκοκκο (

meningococcal

) και µε αδρανοποιηµένο ιό γρίπης (

influenza

), παρόµοια ποσοστά υγιών εθελοντών είτε υπό θεραπεία µε 150 mg secukinumab είτε υπό θεραπεία µε εικονικό φάρµακο ανέπτυξαν επαρκή ανοσολογική απάντηση µε τουλάχιστον τετραπλασιασµό των τίτλων αντισωµάτων κατά του µηνιγγιτιδόκοκκου και της γρίπης. Τα δεδοµένα υποδηλώνουν ότι το Cosentyx δεν καταστέλλει τη χυµική ανοσολογική απάντηση στα εµβόλια του µηνιγγιτιδόκοκκου και της γρίπης. Ταυτόχρονη ανοσοκατασταλτική θεραπεία Στις µελέτες της ψωρίασης, δεν έχουν αξιολογηθεί η ασφάλεια και η αποτελεσµατικότητα του Cosentyx σε συνδυασµό µε ανοσοκατασταλτικά, συµπεριλαµβανοµένων των βιολογικών, ή µε φωτοθεραπεία (βλ. επίσης παράγραφο 4.5). 4.5 Αλληλεπιδράσεις µε άλλα φαρµακευτικά προϊόντα και άλλες µορφές αλληλεπίδρασης ∆εν θα πρέπει να χορηγούνται εµβόλια µε ζώντες µικροοργανισµούς ταυτόχρονα µε το Cosentyx (βλ. επίσης παράγραφο 4.4). ∆εν έχουν πραγµατοποιηθεί µελέτες αλληλεπιδράσεων σε ανθρώπους. ∆εν υπάρχει άµεση απόδειξη για τον ρόλο της IL 17A στην έκφραση των ενζύµων του CYP450. Η σύνθεση κάποιων ενζύµων του CYP450 καταστέλλεται από τα αυξηµένα επίπεδα κυτταροκινών κατά τη διάρκεια χρόνιας φλεγµονής. Εποµένως, οι αντι-φλεγµονώδεις θεραπείες, όπως ο αναστολέας της IL 17A secukinumab, ενδέχεται να οδηγήσουν σε εξοµάλυνση των επιπέδων CYP450 µε επακόλουθη χαµηλότερη έκθεση στα συγχορηγούµενα φάρµακα που µεταβολίζονται µέσω του CYP450. Συνεπώς, δεν µπορεί να αποκλεισθεί η κλινικά σηµαντική επίδραση στα υποστρώµατα του CYP450 µε στενό θεραπευτικό εύρος, η δόση των οποίων εξατοµικεύεται (π.χ. βαρφαρίνη). Κατά την έναρξη της θεραπείας του secuki numab σε ασθενείς που ακολουθούν αγωγή µε φαρµακευτικά προϊόντα τέτοιου τύπου, θα πρέπει να εξετάζεται το ενδεχόµενο παρακολούθησης της θεραπείας. ∆εν παρατηρήθηκε καµία αλληλεπίδραση όταν το Cosentyx συγχορηγήθηκε µε µεθοτρεξάτη (ΜΤΧ) και/ή κορτικοστεροειδή στις µελέτες των αρθρίτιδων (περιλαµβάνουν ασθενείς µε ψωριασική αρθρίτιδα και αγκυλοποιητική σπονδυλίτιδα). 4.6 Γονιµότητα, κύηση και γαλουχία Γυναίκες σε αναπαραγωγική ηλικία Οι γυναίκες αναπαραγωγικής ηλικίας πρέπει να χρησιµοποιούν µια αποτελεσµατική µέθοδο αντισύλληψης κατά τη διάρκεια της θεραπείας και για τουλάχιστον 20 εβδοµάδες µετά τη θεραπεία. Εγκυµοσύνη ∆εν υπάρχουν επαρκή δεδοµένα για τη χρήση του secukinumab σε εγκύους γυναίκες. Μελέτες σε ζώα δεν κατέδειξαν άµεση ή έµµεση τοξικότητα στην εγκυµοσύνη, την ανάπτυξη του εµβρύου, τον τοκετό ή την µεταγεννητική ανάπτυξη (βλ. παράγραφο 5.3). Σαν προληπτικό µέτρο, είναι προτιµητέο να αποφεύγεται η χρήση του Cosentyx κατά τη διάρκεια της εγκυµοσύνης. Θηλασµός ∆εν είναι γνωστό εάν το secukinumab απεκκρίνεται στο ανθρώπινο γάλα. Οι ανοσοσφαιρίνες απεκκρίνονται στο ανθρώπινο γάλα και δεν είναι γνωστό εάν το secuki numab απορροφάται συστηµατικά µετά από κατάποση. Λόγω των πιθανών ανεπιθύµητων ενεργειών από το secukinumab στα θηλάζοντα βρέφη, πρέπει να αποφασισθεί εάν θα διακοπεί ο θηλασµός κατά τη διάρκεια της θεραπείας και έως 20 εβδοµάδες µετά τη θεραπεία ή αν θα διακοπεί η θεραπεία µε Cosentyx, λαµβάνοντας υπόψη το όφελος του θηλασµού για το παιδί και το όφελος της θεραπείας µε Cosentyx για την γυναίκα. Γονιµότητα Η επίδραση του secukinumab στην ανθρώπινη γονιµότητα δεν έχει αξιολογηθεί. Οι µελέτες σε ζώα δεν υποδεικνύουν άµεσες ή έµµεσες επιβλαβείς επιδράσεις στη γονιµότητα (βλ. παράγραφο 5.3). 4.7 Επιδράσεις στην ικανότητα οδήγησης και χειρισµού µηχανών Το Cosentyx δεν ασκεί καµία ή αµελητέα επίδραση στην ικανότητα οδήγησης και χειρισµού µηχανών. 4.8 Ανεπιθύµητες ενέργειες Περίληψη του προφίλ ασφάλειας Συνολικά 6.200 ασθενείς έχουν λάβει θεραπεία µε Cosentyx σε τυφλοποιηµένες και ανοιχτού σχεδιασµού µελέτες σε διάφορες ενδείξεις (ψωρίαση κατά πλάκας, ψωριασική αρθρίτιδα, αγκυλοποιητική σπονδυλίτιδα και άλλα αυτοάνοσα νοσήµατα). Από αυτούς, 3.671 ασθενείς εκτέθηκαν στο Cosentyx επί τουλάχιστον ένα έτος, αντιπροσωπεύοντας έκθεση 6.267 ετών ασθενών. Ανεπιθύµητες ενέργειες στην ψωρίαση κατά πλάκας Τέσσερις ελεγχόµενες µε εικονικό φάρµακο µελέτες φάσης ΙΙΙ στην ψωρίαση κατά πλάκας οµαδοποιήθηκαν προκειµένου να αξιολογηθεί η ασφάλεια του Cosentyx σε σύγκριση µε το εικονικό φάρµακο επί έως και 12 εβδοµάδες µετά την έναρξη της θεραπείας. Συνολικά, αξιολογήθηκαν 2.076 ασθενείς (692 ασθενείς σε 150 mg, 690 ασθενείς σε 300 mg και 694 ασθενείς σε εικονικό φάρµακο). Οι συχνότερα αναφερθείσες ανεπιθύµητες ενέργειες ήταν λοιµώξεις της ανώτερης αναπνευστικής οδού (συχνότερα ρινοφαρυγγίτιδα, ρινίτιδα). Τα περισσότερα συµβάντα ήταν ήπια ή µέτριας σοβαρότητας. Ανεπιθύµητες ενέργειες στην ψωριασική αρθρίτιδα Το Cosentyx µελετήθηκε σε δύο ελεγχόµενες µε εικονικό φάρµακο µελέτες στην ψωριασική αρθρίτιδα µε 1.003 ασθενείς (703 ασθενείς σε Cosentyx και 300 ασθενείς σε εικονικό φάρµακο) για συνολική έκθεση 1.061 ετών-ασθενών έκθεσης στη µελέτη (διάµεση διάρκεια έκθεσης για τους ασθενείς υπό θεραπεία µε secukinumab: 456 ηµέρες στη Mελέτη ΨA 1 και 245 ηµέρες στη Μελέτη ΨA 2). Το προφίλ ασφάλειας που παρατηρήθηκε στους ασθενείς µε ψωριασική αρθίτιδα υπό θεραπεία µε Cosentyx είναι συνεπές µε το προφίλ ασφάλειας στην ψωρίαση. Ανεπιθύµητες ενέργειες στην αγκυλοποιητική σπονδυλίτιδα Το Cosentyx µελετήθηκε σε δύο ελεγχόµενες µε εικονικό φάρµακο µελέτες στην αγκυλοποιητική σπονδυλίτιδα µε 590 ασθενείς (394 ασθενείς σε Cosentyx και 196 ασθενείς σε εικονικό φάρµακο) για συνολικά 755 έτη-ασθενών έκθεσης στη µελέτη (διάµεση διάρκεια έκθεσης για τους ασθενείς υπό θεραπεία µε secukinumab: 469 ηµέρες στη Μελέτη AΣ 1και 460 ηµέρες στη Μελέτη AΣ 2). Το προφίλ ασφάλειας που παρατηρήθηκε στους ασθενείς µε αγκυλοποιητική σπονδυλίτιδα υπό θεραπεία µε Cosentyx είναι συνεπές µε το προφίλ ασφάλειας στην ψωρίαση. Κατάλογος ανεπιθύµητων ενεργειών σε µορφή πίνακα Οι ανεπιθύµητες ενέργειες από τις κλινικές µελέτες στην ψωρίαση, την ψωριασική αρθρίτιδα και την αγκυλοποιητική σπονδυλίτιτδα (Πίνακας 1)αναφέρονται ανά κατηγορία οργανικού συστήµατος σύµφωνα µε το MedDRA. Σε κάθε κατηγορία οργανικού συστήµατος, οι ανεπιθύµητες ενέργειες κατατάσσονται ανά συχνότητα, µε πρώτες τις πιο συχνές αντιδράσεις. Σε κάθε κατηγορία συχνότητας, οι ανεπιθύµητες ενέργειες παρουσιάζονται µε σειρά φθίνουσας βαρύτητας. Επιπλέον, η αντίστοιχη κατηγορία συχνότητας για κάθε ανεπιθύµητη ενέργεια βασίζεται στην ακόλουθη σύµβαση: πολύ συχνές (≥1/10), συχνές (≥1/100 έως <1/10), όχι συχνές (≥1/1.000 έως <1/100), σπάνιες (≥1/10.000 έως <1/1.000), πολύ σπάνιες (<1/10.000).

Πίνακας 1 Κατάλογος ανεπιθύµητων ενεργειών σε κλινικές µελέτες 1 ) Κατηγορία/Οργανικό Σύστηµα

Λοιµώξεις και παρασιτώσεις

Συχνότητα

Πολύ συχνές

Ανεπιθύµητη ενέργεια

Λοιµώξεις του ανώτερου αναπνευστικού συστήµατος Συχνές Όχι συχνές Όχι συχνές Ερπητική λοίµωξη του στόµατος Καντιντίαση του στόµατος Τριχοφυτία των ποδιών Εξωτερική ωτίτιδα Ουδετεροπενία ∆ιαταραχές του αιµοποιητικού και του λεµφικού συστήµατος ∆ιαταραχές του ανοσοποιητικού συστήµατος Οφθαλµικές διαταραχές ∆ιαταραχές του αναπνευστικού συστήµατος, του θώρακα και του µεσοθωράκιου ∆ιαταραχές του γαστρεντερικού συστήµατος Σπάνιες Όχι συχνές Συχνές Συχνές Αναφυλακτικές αντιδράσεις Επιπεφυκίτιδα Ρινόρροια ∆ιάρροια ∆ιαταραχές του δέρµατος και του υποδόριου ιστού Όχι συχνές Κνίδωση 1) Ελεγχόµενες µε εικονικό φάρµακο κλινικές µελέτες (φάσης III) σε ασθενείς µε ψωρίαση κατά πλάκας, ψωριασική αρθρίτιδα και αγκυλοποιητική σπονδυλίτιδα οι οποίοι εκτέθηκαν σε 300 mg, 150 mg, 75 mg ή εικονικό φάρµακο για θεραπεία διάρκειας έως 12 εβδοµάδων (ψωρίαση) ή 16 εβδοµάδες (ΨA και AΣ) Περιγραφή επιλεγµένων ανεπιθύµητων ενεργειών

Λοιµώξεις

Στην ελεγχόµενη µε εικονικό φάρµακο περίοδο των κλινικών µελετών στην ψωρίαση κατά πλάκας (συνολικά 1.382 ασθενείς έλαβαν θεραπεία µε Cosentyx και 694 ασθενείς έλαβαν θεραπεία µε εικονικό φάρµακο επί έως και 12 εβδοµάδες), αναφέρθηκαν λοιµώξεις στο 28,7% των ασθενών υπό θεραπεία µε Cosentyx συγκριτικά µε το 18,9% των ασθενών υπό θεραπεία µε εικονικό φάρµακο. Η πλειοψηφία των λοιµώξεων ήταν µη σοβαρές και ήπιας έως µέτριας βαρύτητας λοιµώξεις της ανώτερης αναπνευστικής οδού, όπως ρινοφαρυγγίτιδα, οι οποίες δεν έχρηζαν διακοπής της θεραπείας. Σηµειώθηκε αύξηση των καντιντιάσεων των βλεννογόνων ή του δέρµατος, συµβατή µε τον µηχανισµό δράσης, αλλά τα περιστατικά ήταν ήπιας ή µέτριας βαρύτητας, µη σοβαρά, ανταποκρινόµενα στην καθιερωµένη θεραπεία και δεν έχρηζαν διακοπής της θεραπείας. Σοβαρές λοιµώξεις παρατηρήθηκαν στο 0,14% των ασθενών υπό θεραπεία µε Cosentyx και στο 0,3% των ασθενών υπό θεραπεία µε εικονικό φάρµακο (βλ. παράγραφο 4.4). Καθ’ όλη την περίοδο θεραπείας (συνολικά 3.430 ασθενείς υπό θεραπεία µε Cosentyx επί έως και 52 εβδοµάδες για την πλειοψηφία των ασθενών), αναφέρθηκαν λοιµώξεις στο 47,5% των ασθενών υπό θεραπεία µε Cosentyx (0,9 ανά έτος παρακολούθησης ασθενούς). Σοβαρές λοιµώξεις αναφέρθηκαν στο 1,2% των ασθενών υπό θεραπεία µε Cosentyx (0,015 ανά έτος παρακολούθησης ασθενούς). Τα ποσοστά λοιµώξεων που παρατηρήθηκαν στις κλινικές µελέτες της ψωριασικής αρθρίτιδας και της αγκυλοποιητικής σπονδυλίτιδας ήταν παρόµοια µε εκείνα που παρατηρήθηκαν στις µελέτες της ψωρίασης. ουδετεροπενίας <0,5x109/l (CTCAE Βαθµού 4).

Αντιδράσεις υπερευαισθησίας

περιπτώσεις αναφυλακτικής αντίδρασης στο Cosentyx (βλ. επίσης παράγραφο 4.4). SOL PF.P 150mg/1ml BTX2 PF.PENX1ml Ν.Τ. 1.097,63 ˜#º# 1.358,77 €

Ουδετεροπενία

Στις κλινικές µελέτες φάσης 3 της ψωρίασης, παρατηρήθηκε ουδετεροπενία πιο συχνά µε το secukinumab απ’ ότι µε το εικονικό φάρµακο, αλλά οι περισσότερες περιπτώσεις ήταν ήπιες, παροδικές και αναστρέψιµες. Ουδετεροπενία <1,0 0,5x109/l (CTCAE Βαθµού 3) αναφέρθηκε σε 18 από τους 3.430 (0,5%) ασθενείς υπό secukinumab, χωρίς δοσολογική και χρονική συσχέτιση µε λοιµώξεις στις 15 από τις 18 περιπτώσεις. ∆εν υπήρξαν αναφορές περιπτώσεων πιο σοβαρής ουδετεροπενίας. Μη-σοβαρές λοιµώξεις µε συνήθη ανταπόκριση στην καθιερωµένη θεραπεία που δεν έχρηζαν διακοπής του Cosentyx αναφέρθηκαν στις υπόλοιπες 3 περιπτώσεις. Η συχνότητα της ουδετεροπενίας στην ψωριασική αρθρίτιδα και την αγκυλοποιητική σπονδυλίτιδα είναι παρόµοια µε εκείνη της ψωρίασης. Αναφέρθηκαν σπάνιες περιπτώσεις Στις κλινικές µελέτες, παρατηρήθηκαν κνίδωση και σπάνιες

Ανοσογονικότητα

Στις κλινικές µελέτες της ψωρίασης, της ψωριασικής αρθρίτιδας και της αγκυλοποιητικής σπονδυλίτιδας, λιγότερο από 1% των ασθενών υπό θεραπεία µε Cosentyx ανέπτυξε αντισώµατα έναντι του secukinumab κατά τη θεραπεία διάρκειας έως και 52 εβδοµάδων. Περίπου τα µισά από τα σχετιζόµενα µε τη θεραπεία αντισώµατα κατά του φαρµάκου ήταν εξουδετερωτικά, αλλά αυτό δεν σχετίστηκε µε απώλεια της αποτελεσµατικότητας ή µε φαρµακοκινητικές ανωµαλίες. Αναφορά πιθανολογούµενων ανεπιθύµητων ενεργειών Η αναφορά πιθανολογούµενων ανεπιθύµητων ενεργειών µετά από τη χορήγηση άδειας κυκλοφορίας του φαρµακευτικού προϊόντος είναι σηµαντική. Επιτρέπει τη συνεχή παρακολούθηση της σχέσης οφέλους-κινδύνου του φαρµακευτικού προϊόντος. Ζητείται από τους επαγγελµατίες του τοµέα της υγειονοµικής περίθαλψης να αναφέρουν οποιεσδήποτε πιθανολογούµενες ανεπιθύµητες ενέργειες µέσω του εθνικού συστήµατος αναφοράς: Εθνικός Οργανισµός Φαρµάκων Μεσογείων 284 GR-15562 Χολαργός, Αθήνα Τηλ: + 30 21 32040380/337 Φαξ: + 30 21 06549585 Ιστότοπος: http://www.eof.gr 4.9 Υπερδοσολογία ∆εν έχουν αναφερθεί περιπτώσεις υπερδοσολογίας στις κλινικές µελέτες. ∆όσεις έως και 30 mg/kg (περίπου 2.000 έως 3.000 mg) έχουν χορηγηθεί ενδοφλεβίως στις κλινικές µελέτες χωρίς δοσοπεριοριστική τοξικότητα. Σε περίπτωση υπερδοσολογίας, συνιστάται η παρακολούθηση του ασθενούς για σηµεία ή συµπτώµατα ανεπιθύµητων ενεργειών και άµεση έναρξη κατάλληλης συµπτωµατικής θεραπείας. 6. ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ 6.1 Κατάλογος εκδόχων Τρεχαλόζη διϋδρική L ιστιδίνη L ιστιδίνη υδροχλωρική µονοϋδρική L µεθειονίνη Πολυσορβικό 80 Ύδωρ για ενέσιµα 6.2 Ασυµβατότητες Ελλείψει µελετών σχετικά µε τη συµβατότητα, το παρόν φαρµακευτικό προϊόν δεν πρέπει να αναµειγνύεται µε άλλα φαρµακευτικά προϊόντα. 6.3 ∆ιάρκεια ζωής 18 µήνες 6.4 Ιδιαίτερες προφυλάξεις κατά τη φύλαξη του προϊόντος Φυλάσσετε σε ψυγείο (2°C - 8°C). Μην καταψύχετε. Φυλάσσετε τις σύριγγες στην αρχική συσκευασία για να προστατεύονται από το φως. Φυλάσσετε σε ψυγείο (2°C - 8°C). Μην καταψύχετε. Φυλάσσετε τις πένες στην αρχική συσκευασία για να προστατεύονται από το φως. 6.5 Φύση και συστατικά του περιέκτη Το Cosentyx διατίθεται σε γυάλινη προγεµισµένη σύριγγα του 1 ml µε ελαστική κεφαλή εµβόλου επικαλυµµένη µε FluroTec, βελόνα 27G x ½" και σκληρό κάλυµµα βελόνας από ελαστικό στυρολίου βουταδιενίου τοποθετηµένη σε συσκευή παθητικής ασφάλειας από πολυκαρβονικό. Το Cosentyx διατίθεται σε προγεµισµένη σύριγγα µίας χρήσεως τοποθετηµένη σε πένα τριγωνικού σχήµατος µε διαφανές παράθυρο και ετικέτα (πένα SensoReady). Η προγεµισµένη σύριγγα στο εσωτερικό της πένας είναι µια γυάλινη σύριγγα του 1 ml µε ελαστική κεφαλή εµβόλου επικαλυµµένη µε FluroTec, βελόνα 27G x ½" και σκληρό κάλυµµα βελόνας από ελαστικό στυρολίου βουταδιενίου. Το Cosentyx διατίθεται σε µονές συσκευασίες που περιέχουν 1 ή 2 προγεµισµένες σύριγγες και σε πολυσυσκευασίες που περιέχουν 6 (3 συσκευασίες των 2) προγεµισµένες σύριγγες. Μπορεί να µην κυκλοφορούν όλες οι συσκευασίες. Το Cosentyx διατίθεται σε µονές συσκευασίες που περιέχουν 1 ή 2 προγεµισµένες πένες και σε πολυσυσκευασίες που περιέχουν 6 (3 συσκευασίες των 2) προγεµισµένες πένες. Μπορεί να µην κυκλοφορούν όλες οι συσκευασίες 6.6 Ιδιαίτερες προφυλάξεις απόρριψης και άλλος χειρισµός Το Cosentyx 150 mg ενέσιµο διάλυµα διατίθεται σε προγεµισµένη σύριγγα µίας χρήσης για ατοµική χρήση. Μην ανακινείτε ή καταψύχετε την σύριγγα. Η σύριγγα πρέπει να βγαίνει από το ψυγείο 20 λεπτά πριν από την ένεση προκειµένου να έλθει σε θερµοκρασία δωµατίου. Πριν από τη χρήση συνιστάται ο οπτικός έλεγχος της προγεµισµένης σύριγγας. Το υγρό πρέπει να είναι διαυγές. Το χρώµα του µπορεί να κυµαίνεται από άχρωµο σε ελαφρώς κίτρινο. Μπορεί να δείτε µία µικρή φυσαλίδα αέρα, κάτι που είναι φυσιολογικό. Να µην χρησιµοποιείται εάν το υγρό περιέχει ευδιάκριτα σωµατίδια, είναι θολό ή ευκρινώς καφέ. Λεπτοµερείς οδηγίες σχετικά µε τη χρήση παρέχονται στο φύλλο οδηγιών χρήσης. Κάθε αχρησιµοποίητο φαρµακευτικό προϊόν ή υπόλειµµα πρέπει να απορρίπτεται σύµφωνα µε τις κατά τόπους ισχύουσες σχετικές διατάξεις. Το Cosentyx 150 mg ενέσιµο διάλυµα διατίθεται σε προγεµισµένη πένα µίας χρήσης για ατοµική χρήση. Μην ανακινείτε ή καταψύχετε την πένα. Η πένα πρέπει να βγαίνει από το ψυγείο 20 λεπτά πριν από την ένεση προκειµένου να έλθει σε θερµοκρασία δωµατίου. Πριν από τη χρήση συνιστάται ο οπτικός έλεγχος της προγεµισµένης πένας Το υγρό πρέπει να είναι διαυγές. Το χρώµα του µπορεί να κυµαίνεται από άχρωµο σε ελαφρώς κίτρινο. Μπορεί να δείτε µία µικρή φυσαλίδα αέρα, κάτι που είναι φυσιολογικό. Να µην χρησιµοποιείται εάν το υγρό περιέχει ευδιάκριτα σωµατίδια, είναι θολό ή ευκρινώς καφέ. Λεπτοµερείς οδηγίες σχετικά µε τη χρήση παρέχονται στο φύλλο οδηγιών χρήσης. Κάθε αχρησιµοποίητο φαρµακευτικό προϊόν ή υπόλειµµα πρέπει να απορρίπτεται σύµφωνα µε τις κατά τόπους ισχύουσες σχετικές διατάξεις. 7. ΚΑΤΟΧΟΣ ΤΗΣ Α∆ΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ Novartis Europharm Limited Frimley Business Park Camberley GU16 7SR United Kingdom 8. ΑΡΙΘΜΟΣ(ΟΙ) Α∆ΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ EU/1/14/980/002 EU/1/14/980/003 EU/1/14/980/006 EU/1/14/980/004 EU/1/14/980/005 EU/1/14/980/007 9. ΗΜΕΡΟΜΗΝΙΑ ΠΡΩΤΗΣ ΕΓΚΡΙΣΗΣ / ΑΝΑΝΕΩΣΗΣ ΤΗΣ Α∆ΕΙΑΣ 15.01.2015 10. ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ 19.11.2015 Λεπτοµερή πληροφοριακά στοιχεία για το παρόν φαρµακευτικό προϊόν είναι διαθέσιµα στον δικτυακό τόπο του Ευρωπαϊκού Οργανισµού Φαρµάκων http://www.ema.europa.eu ΣΥΣΚΕΥΑΣΙΑ/ΤΙΜΗ Cosentyx INJ.

Cosentyx INJ.SOL 150mg/1ml PF.SYR. BTX2 PF.SYR.X1ml Ν.Τ. 1.097,63 ˜#º# 1.358,77 € ΤΡΟΠΟΣ ∆ΙΑΘΕΣΗΣ: Με περιορισµένη ιατρική συνταγή. Η διάγνωση και/ή η έναρξη της θεραπείας γίνεται σε νοσοκοµείο και µπορεί να συνεχίζεται και εκτός νοσοκοµείου υπό την παρακολούθηση ειδικού ιατρού. ”ÌÅÒ¹ÐÑÂ˾ĺËÌÖËѾßÏʾȾÍÆ̾ÐÃ¾É¹È¾Æ ‘˾øÏÂÑ ¡†•ŒÑÆÔ¾ËÂÍÆÒ½ÊÅÑÂÔÂ˸ÏÄÂÆÂÔÄƾ ¡†‘ѾßÏʾȾ ŒÖÊÍÉÅÏÎËÌËѾÔÑÅˤ™˜£¢˜ —™‘¢£‘¥

ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει τον ταχύ προσ διορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες του τομέα της υγειο νομικής περίθαλψης να αναφέρουν οποιεσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες.

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:

OLYSIO 150 mg καψάκια, σκληρά.

ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:

μονοϋδρική). Κάθε σκληρό καψάκιο περιέχει νατριούχο σιμεπρεβίρη που ισοδυναμεί με 150 mg σιμεπρεβίρης. Έκδοχο με γνωστές δράσεις: κάθε καψάκιο περιέχει 78,4 mg λακτόζης (ως

ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:

Σκληρό καψάκιο (καψάκιο). Λευκό καψάκιο ζελατίνης μήκους περίπου 22 mm, με την ένδειξη “TMC435 150” με μαύρο μελάνι.

ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:

Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Βέλγιο.

ΑΡΙΘ ΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:

EU/1/14/924/002 (28 καψακίων).

ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩ ΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:

20 Αυγούστου 2015. Λεπτομερή πληροφοριακά στοιχεία για το παρόν φαρμακευτικό προϊόν είναι διαθέσιμα στον δικτυακό τόπο του Ευρωπαϊκού Οργανισμού Φαρμάκων: http://www.ema.europa.eu.

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ:

Περιορισμένη ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής.

ΣΥΣΚΕΥΑΣΙΑ / ΤΙΜΗ Περιεκτικότητα

ΣΚΛΗΡΟ ΚΑΨΑΚΙΟ 150MG/CAP

Μέγεθος συσκευασίας

BT x 28 CAPS (4 BLISTER x 7 CAPS)

Λιανική τιμή

9.094,89

Nοσοκομειακή τιμή

7.563,03€

JANSSEN-CILAG ΦΑΡΜΑΚΕΥΤΙΚΗ A.E.B.E.

Λεωφόρος Ειρήνης 56, 151 21, Πεύκη, Αθήνα, Τηλ.: 210 8090000 www.janssen.com.gr

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

  



     

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Η διαφήμιση είναι σύμφωνη με την ισχύουσα νομοθεσία - Υπουργική Απόφαση ∆ΥΓ3(α)ΓΠ 32221 - ΦΕΚ B’ 1049/29.4.2013 και τον κώδικα δεοντολογίας του ΣΦΕΕ.

Πριν τη συνταγογράφηση συμβουλευθείτε την πλήρη Περίληψη Χαρακτηριστικών των Προϊόντων. Για περισσότερες πληροφορίες απευθυνθείτε στην εταιρεία:

AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.

Μαρίνου Αντύπα 41-45, Νέο Ηράκλειο, 14121, Τηλ.: 214 4165555